<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001835.pub4" GROUP_ID="PVD" ID="959499072011402360" MERGED_FROM="" MODIFIED="2015-02-06 08:06:21 +0000" MODIFIED_BY="Marlene Stewart" REVIEW_NO="072d" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="8.0">
<COVER_SHEET MODIFIED="2015-02-06 08:06:21 +0000" MODIFIED_BY="Marlene Stewart">
<TITLE>Surgery for small asymptomatic abdominal aortic aneurysms</TITLE>
<CONTACT MODIFIED="2015-02-06 08:06:21 +0000" MODIFIED_BY="Marlene Stewart"><PERSON ID="49025F3882E26AA200991D56D04D2945" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Giovanni</FIRST_NAME><LAST_NAME>Filardo</LAST_NAME><POSITION>Director of Epidemiology</POSITION><EMAIL_1>GiovanFi@BaylorHealth.edu</EMAIL_1><ADDRESS><DEPARTMENT>Department of Epidemiology, Office of the Chief Quality Officer</DEPARTMENT><ORGANISATION>Baylor Scott and White Health</ORGANISATION><CITY>Dallas</CITY><REGION>Texas</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+1 214 2653633</PHONE_1><FAX_1>+1 214 2653640</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2015-02-06 08:06:21 +0000" MODIFIED_BY="Marlene Stewart"><PERSON ID="49025F3882E26AA200991D56D04D2945" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Giovanni</FIRST_NAME><LAST_NAME>Filardo</LAST_NAME><POSITION>Director of Epidemiology</POSITION><EMAIL_1>GiovanFi@BaylorHealth.edu</EMAIL_1><ADDRESS><DEPARTMENT>Department of Epidemiology, Office of the Chief Quality Officer</DEPARTMENT><ORGANISATION>Baylor Scott and White Health</ORGANISATION><CITY>Dallas</CITY><REGION>Texas</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+1 214 2653633</PHONE_1><FAX_1>+1 214 2653640</FAX_1></ADDRESS></PERSON><PERSON ID="17822" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Janet</FIRST_NAME><MIDDLE_INITIALS>T</MIDDLE_INITIALS><LAST_NAME>Powell</LAST_NAME><EMAIL_1>j.powell@imperial.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Vascular Surgery Research Group</DEPARTMENT><ORGANISATION>Imperial College London</ORGANISATION><ADDRESS_1>Charing Cross Campus</ADDRESS_1><CITY>London</CITY><ZIP>W6 8RP</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 208 846 7312</PHONE_1><FAX_1>+44 208 846 7330</FAX_1></ADDRESS></PERSON><PERSON ID="89117749231684277793111101105736" ROLE="AUTHOR"><PREFIX>Miss</PREFIX><FIRST_NAME>Melissa Ashley-Marie</FIRST_NAME><LAST_NAME>Martinez</LAST_NAME><EMAIL_1>melissa.ashley.marie@gmail.com</EMAIL_1><EMAIL_2>melissma@live.unc.edu</EMAIL_2><MOBILE_PHONE>505-929-4480</MOBILE_PHONE><ADDRESS><DEPARTMENT>Department of Internal Medicine</DEPARTMENT><ORGANISATION>University of New Mexico</ORGANISATION><CITY>Albuquerque</CITY><REGION>New Mexico</REGION><COUNTRY CODE="US">USA</COUNTRY></ADDRESS></PERSON><PERSON ID="15705" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>David</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Ballard</LAST_NAME><SUFFIX>MD, PhD, FACP</SUFFIX><POSITION>Senior Vice President and Chief Quality Officer, Executive Director and BHCS Endowed Chair</POSITION><EMAIL_1>dj.ballard@baylorhealth.edu</EMAIL_1><ADDRESS><DEPARTMENT>Office of the Chief Quality Officer</DEPARTMENT><ORGANISATION>Baylor Scott and White Health</ORGANISATION><CITY>Dallas</CITY><REGION>Texas</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+1 214-265-3670</PHONE_1><FAX_1>+1 214-265-3640</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2014-10-02 14:38:41 +0100" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="13" MONTH="2" YEAR="2014"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="13" MONTH="2" YEAR="2014"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="13" MONTH="2" YEAR="2016"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="1999"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="1999"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2015"/>
</DATES>
<WHATS_NEW MODIFIED="2015-02-06 08:00:14 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2015-02-06 08:00:07 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="26" MONTH="6" YEAR="2014"/>
<DESCRIPTION>
<P>Searches re-run. No new studies included. </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2015-02-06 08:00:14 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="26" MONTH="6" YEAR="2014"/>
<DESCRIPTION>
<P>Searches re-run. No new studies included. Relevant review sections updated according to current Cochrane standards. Conclusions not changed.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2014-04-04 08:22:07 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-04-04 08:22:07 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="17" MONTH="10" YEAR="2011"/>
<DESCRIPTION>
<P>New author added</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2014-04-04 08:22:04 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="17" MONTH="10" YEAR="2011"/>
<DESCRIPTION>
<P>CAESAR and PIVOTAL results included in the analysis</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2011-10-26 17:48:27 +0100" MODIFIED_BY="Marlene Stewart">
<DATE DAY="20" MONTH="5" YEAR="2008"/>
<DESCRIPTION>
<P>ADAM trial results incorporated in analysis. CAESAR and PIVOTAL trials added to ongoing studies.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2011-10-26 17:48:24 +0100" MODIFIED_BY="Marlene Stewart">
<DATE DAY="8" MONTH="4" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2015-01-14 09:05:35 +0000" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES MODIFIED="2015-01-14 09:05:35 +0000" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2015-01-14 09:05:35 +0000" MODIFIED_BY="[Empty name]">
<NAME>The Chief Scientist Office, Scottish Government Health Directorates, the Scottish Government</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>The PVD Group editorial base is supported by the Chief Scientist Office.</P>
</DESCRIPTION>
</SOURCE>
<SOURCE MODIFIED="2011-11-15 15:16:59 +0000" MODIFIED_BY="[Empty name]">
<NAME>National Institute for Health Research (NIHR)</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>The PVD Group editorial base is supported by a programme grant from the NIHR.</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2015-02-06 07:52:09 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2015-01-14 09:01:11 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-07-17 12:32:15 +0100" MODIFIED_BY="[Empty name]">Surgery for small abdominal aortic aneurysms that do not cause symptoms</TITLE>
<SUMMARY_BODY MODIFIED="2015-01-14 09:01:11 +0000" MODIFIED_BY="[Empty name]">
<P>An aneurysm is a ballooning of an artery (blood vessel), which, in the case of an abdominal aortic aneurysm (AAA), occurs in the major artery in the abdomen (aorta). Ruptured AAAs cause death unless surgical repair is rapid, which is difficult to achieve. Surgery is considered necessary for people with aneurysms of more than 5.5 cm in diameter or who have associated pain, to relieve symptoms and to reduce the risk of rupture and death. However, risks are associated with surgery. Surgical repair consists of insertion of a prosthetic inlay graft, either by open surgery or endovascular repair.</P>
<P>Small asymptomatic AAAs are at low risk of rupture and are monitored through regular imaging so they can be surgically repaired if they subsequently enlarge. This review identified four well-conducted, controlled trials that randomised 3314 participants with small (diameter 4.0 cm to 5.5 cm) asymptomatic AAAs to immediate repair or regular, routine ultrasounds to check for aneurysm growth (surveillance). Among the patients randomised to surveillance, the aneurysm was repaired if it was enlarging, reached 5.5 cm in diameter, or became symptomatic. The four trials showed an early survival benefit in the surveillance group because of the number of deaths within 30 days of surgery (operative mortality). The trials did not show a meaningful difference in long-term survival between immediate repair and selective surveillance over the three to eight years of follow-up. Some 31% to 75% of the participants randomised to surveillance eventually had the aneurysm repaired. Overall, the risk of bias within the included studies was low and the quality of the evidence high. The results from the four trials conducted to date suggest no overall advantage to immediate surgery for small AAAs (4.0 cm to 5.5 cm). A pooled analysis of the two trials comparing immediate open surgical repair to surveillance demonstrated that this result holds true regardless of patient age or aneurysm size (within the range of 4.0 cm to 5.5 cm diameter). Furthermore, the more recent trials, which focused on the efficacy of endovascular repair, also failed to show a benefit over surveillance. Quality-of-life results among trials were conflicting. Thus, neither immediate open nor immediate endovascular repair of small AAAs is supported by the current evidence.<BR/>
</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2015-02-04 10:12:07 +0000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2015-01-14 09:00:20 +0000" MODIFIED_BY="[Empty name]">
<P>An abdominal aortic aneurysm (AAA) is an abnormal ballooning of the major abdominal artery. Some AAAs present as emergencies and require surgery; others remain asymptomatic. Treatment of asymptomatic AAAs depends on many factors, but an important one is the size of the aneurysm, as risk of rupture increases with aneurysm size. Large asymptomatic AAAs (greater than 5.5 cm in diameter) are usually repaired surgically; very small AAAs (less than 4.0 cm diameter) are monitored with ultrasonography. Debate continues over the appropriate roles of immediate repair and surveillance with repair on subsequent enlargement in people presenting with asymptomatic AAAs of 4.0 cm to 5.5 cm diameter. This is the third update of the review first published in 1999.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2015-01-14 09:00:23 +0000" MODIFIED_BY="[Empty name]">
<P>To compare mortality, quality of life, and cost effectiveness of immediate surgical repair versus routine ultrasound surveillance in people with asymptomatic AAAs between 4.0 cm and 5.5 cm in diameter.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2015-01-14 09:00:29 +0000" MODIFIED_BY="[Empty name]">
<P>For this update, the Cochrane Peripheral Vascular Diseases Group Trials Search Co-ordinator searched the Specialised Register (February 2014) and the Cochrane Central Register of Controlled Trials (CENTRAL; 2014, Issue 1). We checked reference lists of relevant articles for additional studies.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2015-01-14 09:00:30 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials in which men and women with asymptomatic AAAs of diameter 4.0 cm to 5.5 cm were randomly allocated to immediate repair or imaging-based surveillance at least every six months. Outcomes had to include mortality or survival.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2015-01-14 09:00:40 +0000" MODIFIED_BY="[Empty name]">
<P>Three members of the review team independently extracted the data, which were cross-checked by other team members. Risk ratios (RR) (endovascular aneurysm repair only), hazard ratios (HR) (open repair only), and 95% confidence intervals based on Mantel-Haenszel Chi<SUP>2</SUP> statistic were estimated at one and six years (open repair only) following randomisation. We included all relevant published studies in this review.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2015-02-04 10:12:07 +0000" MODIFIED_BY="[Empty name]">
<P>For this update, four trials with a combined total of 3314 participants fulfilled the inclusion criteria. Two trials compared surveillance with immediate open repair; two trials compared surveillance with immediate endovascular repair. Overall, the risk of bias within the included studies was low and the quality of the evidence high. The four trials showed an early survival benefit in the surveillance group (due to 30-day operative mortality with surgery) but no significant differences in long-term survival (adjusted HR 0.88, 95% confidence interval (CI) 0.75 to 1.02, mean follow-up 10 years; HR 1.21, 95% CI 0.95 to 1.54, mean follow-up 4.9 years; HR 0.76, 95% CI 0.30 to 1.93, median follow-up 32.4 months; HR 1.01, 95% CI 0.49 to 2.07, mean follow-up 20 months). A pooled analysis of participant-level data from two trials (with a maximum follow-up of seven to eight years) showed no statistically significant difference in survival between immediate open repair and surveillance (propensity score-adjusted HR 0.99; 95% CI 0.83 to 1.18), and that this lack of treatment effect did not vary by AAA diameter (P = 0.39) or participant age (P = 0.61). The meta-analysis of mortality at one year for the endovascular trials likewise showed no significant association (RR at one year 1.15, 95% CI 0.60 to 2.17). Quality-of-life results among trials were conflicting.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2015-01-14 09:00:59 +0000" MODIFIED_BY="[Empty name]">
<P>The results from the four trials to date demonstrate no advantage to immediate repair for small AAA (4.0 cm to 5.5 cm), regardless of whether open or endovascular repair is used and, at least for open repair, regardless of patient age and AAA diameter. Thus, neither immediate open nor immediate endovascular repair of small AAAs is supported by currently available evidence.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2015-02-04 10:12:37 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2015-02-04 10:12:37 +0000" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2015-01-14 09:01:23 +0000" MODIFIED_BY="[Empty name]">
<P>An aneurysm is an abnormal dilatation of an artery. This can occur in any artery including the abdominal aorta, below the branches to the renal arteries (<LINK REF="REF-Ernst-1993" TYPE="REFERENCE">Ernst 1993</LINK>; <LINK REF="REF-Stonebridge-1996" TYPE="REFERENCE">Stonebridge 1996</LINK>). Abdominal aortic aneurysms (AAAs) are rare in people under 50 years of age, but thereafter prevalence increases sharply with increasing age (<LINK REF="REF-Lederle-1997" TYPE="REFERENCE">Lederle 1997</LINK>; <LINK REF="REF-Lederle-2000" TYPE="REFERENCE">Lederle 2000</LINK>
<B>)</B>. AAAs occur in about 5% of men aged 65 to 74 years and are approximately 3 times more common in men than in women (<LINK REF="REF-Lederle-1997a" TYPE="REFERENCE">Lederle 1997a</LINK>; <LINK REF="REF-Lederle-2000" TYPE="REFERENCE">Lederle 2000</LINK>). Low prevalence rates have been observed for African-American males compared to white males, and black race has been identified as having a strong negative association with AAA (<LINK REF="REF-Lederle-1997" TYPE="REFERENCE">Lederle 1997</LINK>; <LINK REF="REF-Lederle-2000" TYPE="REFERENCE">Lederle 2000</LINK>). 
</P>
<P>The cause of AAA is likely to be multifactorial (<LINK REF="REF-Shah-1997" TYPE="REFERENCE">Shah 1997</LINK>). It may result from a change in the composition of the collagen and elastin matrix in the media of the arterial wall due to excessive proteolysis. AAAs often coincide with atherosclerosis in the aortic wall, but it is not known if atherosclerosis is involved in the pathogenesis of aneurysms. Inflammation of the aortic wall also appears to be influential. The main well-established risk factor is cigarette smoking, with smokers having a two- to three-fold increased risk of AAA compared to nonsmokers (<LINK REF="REF-Lederle-1997" TYPE="REFERENCE">Lederle 1997</LINK>; <LINK REF="REF-Lederle-2003" TYPE="REFERENCE">Lederle 2003</LINK>). Aneurysms also occur more frequently in close relatives of people who have suffered an AAA, but a mode of inheritance has not been demonstrated (<LINK REF="REF-Ballard-1999" TYPE="REFERENCE">Ballard 1999</LINK>).</P>
<P>The progression of AAA can vary considerably (<LINK REF="REF-Ernst-1993" TYPE="REFERENCE">Ernst 1993</LINK>). Some people remain asymptomatic (no evidence of significant groin, back, or abdominal pain) throughout life, while others present with symptoms such as back pain, pulsating abdominal mass, or pulsating popliteal/femoral artery, or as emergencies following rupture. The risk of rupture increases with aneurysm size; mortality following rupture is high (approximately 60% die before reaching hospital) (<LINK REF="REF-Ballard-1999" TYPE="REFERENCE">Ballard 1999</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2015-01-14 09:01:30 +0000" MODIFIED_BY="[Empty name]">
<P>Ruptured AAAs require emergency surgical repair, which has a mortality rate of 40% to 50%. The outcome of surgery is highly dependent on the patient's presenting features, including general clinical condition (<LINK REF="REF-Ernst-1993" TYPE="REFERENCE">Ernst 1993</LINK>; <LINK REF="REF-Stonebridge-1996" TYPE="REFERENCE">Stonebridge 1996</LINK>). Surgery for patients with symptomatic AAAs is considered necessary to relieve symptoms and to reduce the risk of rupture and death.</P>
<P>In the case of asymptomatic AAAs, however, management depends on the size of the aneurysm. To date, no medical therapy has been shown to reduce the rate of size change or risk of rupture among people with asymptomatic AAAs (<LINK REF="REF-Ballard-1999" TYPE="REFERENCE">Ballard 1999</LINK>; <LINK REF="REF-Ernst-1993" TYPE="REFERENCE">Ernst 1993</LINK>; <LINK REF="STD-UKSAT" TYPE="STUDY">UKSAT</LINK>); however, randomised controlled trials examining the efficacy of exercise, doxycycline, and angiotensin converting enzyme inhibitors in limiting AAA progression are under way (<LINK REF="REF-Golledge-2011" TYPE="REFERENCE">Golledge 2011</LINK>). Surgery is performed on larger aneurysms (greater than 5.5 cm in diameter), while very small aneurysms (less than 4.0 cm in diameter), in which the risk of rupture is low, are monitored for growth through regular imaging, usually ultrasonography. For small AAAs (4.0 cm to 5.5 cm diameter), there has been considerable debate as to the most beneficial course of treatment, that is immediate repair versus surveillance and selective repair of AAAs that subsequently enlarge (<LINK REF="REF-Lederle-1996" TYPE="REFERENCE">Lederle 1996</LINK>). Much of this debate centres around the uncertainty of risk of rupture for small AAAs.</P>
</INTERVENTION>
<THEORY MODIFIED="2015-01-14 09:01:45 +0000" MODIFIED_BY="[Empty name]">
<P>A literature review conducted by a RAND Corporation panel in 1991 assessed the appropriateness and necessity of surgery for AAAs and found reports of risk of rupture, based on referral case series, as high as 5% per year for AAAs greater than 5.0 cm and 3% to 5% per year for AAAs equal to or less than 5.0 cm (<LINK REF="REF-Ballard-1992" TYPE="REFERENCE">Ballard 1992</LINK>), which supports arguments in favour of the aggressive approach of immediate repair. Population data, however, suggest that risk of rupture for AAAs less than 5.0 cm is less than 1% per year, under which scenario the merits of selective surveillance are apparent (<LINK REF="REF-Ballard-1992" TYPE="REFERENCE">Ballard 1992</LINK>; <LINK REF="REF-Nevitt-1989" TYPE="REFERENCE">Nevitt 1989</LINK>). Recent evidence suggests the risk of rupture can be lowered even further through pharmacologic management, such as use of statins and angiotensin converting enzyme inhibitors (<LINK REF="REF-Hackam-2006" TYPE="REFERENCE">Hackam 2006</LINK>; <LINK REF="REF-Mosorin-2008" TYPE="REFERENCE">Mosorin 2008</LINK>; <LINK REF="REF-Powell-2008" TYPE="REFERENCE">Powell 2008</LINK>). Similarly, population studies suggest that early reports of expansion rates of approximately 0.4 cm per year for AAAs between 4.0 cm and 6.0 cm in diameter had overestimated growth by approximately 0.2 cm per year (<LINK REF="REF-Bernstein-1984" TYPE="REFERENCE">Bernstein 1984</LINK>; <LINK REF="REF-Nevitt-1989" TYPE="REFERENCE">Nevitt 1989</LINK>), inaccurately favouring aggressive intervention. A recent meta-analysis pooling individual patient data for more than 15,000 patients included in studies of small AAA growth and rupture found increasing growth rates with increasing diameters, but estimated that to control the risk of rupture to less than 1%, a surveillance interval of only once every 8.5 years (95% confidence interval (CI) 7.0 to 10.5) would be necessary in a man with a 3.0 cm AAA; or once in 17 months (95% CI 14 to 22) in a man with a 5.0 cm AAA (<LINK REF="REF-Bown-2013" TYPE="REFERENCE">Bown 2013</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2015-02-04 10:12:37 +0000" MODIFIED_BY="[Empty name]">
<P>The 'grey area' of care for small AAAs, resulting from the uncertainty surrounding the risk of rupture versus the risk of intervention and expansion rates identified by the RAND panel, highlighted the need for randomised controlled trials comparing immediate surgery and selective surveillance as treatment options. This led to the design of the Aneurysm Detection and Management (ADAM) trial (<LINK REF="STD-ADAM" TYPE="STUDY">ADAM</LINK>), the United Kingdom Small Aneurysm Trial (UKSAT) (<LINK REF="STD-UKSAT" TYPE="STUDY">UKSAT</LINK>), and the <LINK REF="STD-Canadian-Trial" TYPE="STUDY">Canadian Trial</LINK>, which used open surgery to perform the repairs. Later, when endovascular repair became available, the Comparison of Surveillance Versus Aortic Endografting for Small Aneurysm Repair (<LINK REF="STD-CAESAR" TYPE="STUDY">CAESAR</LINK>) and the Positive Impact of Endovascular Options for Treating Aneurysms Early (<LINK REF="STD-PIVOTAL" TYPE="STUDY">PIVOTAL</LINK>) were conducted, using endovascular repair as the surgical option. Most recently, pooling the participant-level data from the ADAM and UKSAT trials has enabled the investigation of the possibility that age or AAA diameter might affect survival differences between immediate repair and surveillance (<LINK REF="REF-Filardo--2013" TYPE="REFERENCE">Filardo 2013</LINK>; <LINK REF="REF-Filardo-2014" TYPE="REFERENCE">Filardo 2014</LINK>). As the current guidelines for management of AAA state, &#8220;[d]ebate remains for patients presenting with AAAs between 4.0 cm and 5.4 cm regarding the most appropriate role for either immediate treatment or surveillance and selective repair for those aneurysms that subsequently enlarge beyond 5.4 cm&#8221; (<LINK REF="REF-Chaikof-2009" TYPE="REFERENCE">Chaikof 2009</LINK>). This review synthesised the existing evidence regarding those management strategies.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2015-01-14 09:01:50 +0000" MODIFIED_BY="[Empty name]">
<P>To compare mortality, quality of life, and cost effectiveness of immediate surgical repair versus routine ultrasound surveillance in people with asymptomatic AAAs between 4.0 cm and 5.5 cm in diameter.</P>
</OBJECTIVES>
<METHODS MODIFIED="2015-01-14 09:06:17 +0000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2015-01-14 09:06:07 +0000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2015-01-14 09:01:51 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials (RCTs) in which participants were randomly allocated to immediate surgery versus ultrasound surveillance.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2015-01-14 09:06:02 +0000" MODIFIED_BY="[Empty name]">
<P>Men or women of any age with an asymptomatic AAA. The aneurysm was restricted to the abdominal aorta distal to the renal arteries. The maximum antero-posterior diameter, measured using ultrasound or computerised tomography (CT) scanning, must have been at least 4.0 cm and less than 5.5 cm. The aneurysm should have been non-tender on examination and the patient assessed as generally fit for surgery.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2012-01-31 23:15:53 +0000" MODIFIED_BY="[Empty name]">
<P>Surgical repair of the aneurysm consisting of insertion of a prosthetic inlay graft either by open surgery (abdominal or retroperitoneal route) or by endovascular repair. Surveillance of the maximum antero-posterior diameter was to be performed regularly, with a maximum interval of six months.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2015-01-14 09:06:07 +0000" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2015-01-14 09:01:51 +0000" MODIFIED_BY="[Empty name]">
<P>The outcome measures included at least one of the following:</P>
<UL>
<LI>life expectancy, expected number of years of life remaining following randomisation;</LI>
<LI>mortality, death rate during a specified period of time following randomisation;</LI>
<LI>quality of life, a standard generic measure using a validated instrument encompassing typical domains such as pain, health perceptions, mental health, and physical and social functioning.</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2015-01-14 09:06:07 +0000" MODIFIED_BY="[Empty name]">
<P>The costs, from trial data, a specific survey, or routine statistics, which might have included:</P>
<UL>
<LI>direct hospital costs, all hospital costs attributable to inpatient stays, surgery, and outpatient attendances including ultrasound surveillance;</LI>
<LI>other health service costs, non-hospital costs such as general practitioner attendances, ambulance transfers, convalescence;</LI>
<LI>societal costs, non-health service costs to society such as loss of productivity, time off work, sickness benefit.</LI>
</UL>
<P>The following outcome measures were of interest but were not included in a meta-analysis because they were relevant to only one arm of a trial or were of doubtful validity:</P>
<UL>
<LI>cause of death, mortality by underlying cause of death according to the International Classification of Diseases;</LI>
<LI>operative mortality, measured as 30-day or 'in hospital' mortality;</LI>
<LI>rupture, rate of aneurysm rupture diagnosed at postmortem, operation, or certified as the underlying cause of death.</LI>
</UL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2015-01-14 09:01:59 +0000" MODIFIED_BY="[Empty name]">
<P>
<BR/>
</P>
<ELECTRONIC_SEARCHES MODIFIED="2015-01-14 08:10:50 +0000" MODIFIED_BY="[Empty name]">
<P>For this update, the Cochrane Peripheral Vascular Diseases Group Trials Search Co-ordinator (TSC) searched the Specialised Register (February 2014) and the Cochrane Central Register of Controlled Trials (CENTAL) (2014, Issue 1), part of <I>The Cochrane Library</I> (www.thecochranelibrary.com). See <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> for details of the search strategy used to search CENTRAL. The Specialised Register is maintained by the TSC and is constructed from weekly electronic searches of MEDLINE, EMBASE, CINAHL, AMED, and through handsearching relevant journals. The full list of the databases, journals, and conference proceedings which have been searched, as well as the search strategies used, are described in the (<A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/PVD/frame.html">Specialised Register</A>) section of the Cochrane Peripheral Vascular Diseases Group module in <I>The Cochrane Library </I>(<A HREF="http://www.thecochranelibrary.com">www.thecochranelibrary.com</A>).</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2015-01-14 09:01:59 +0000" MODIFIED_BY="[Empty name]">
<P>We checked the reference lists of relevant studies. We supplemented the searches with information from experts in the field and from handsearches of the following conference proceedings.</P>
<UL>
<LI>The International Society for Vascular Surgery Congress (through to 2011)</LI>
<LI>The Society for Vascular Surgery Annual Meeting (through to 2013)</LI>
<LI>The Society for Clinical Vascular Surgery Annual Symposium (through to 2014)</LI>
<LI>The European Society for Vascular Surgery Annual Meeting (through to 2013)</LI>
</UL>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2015-01-14 09:06:17 +0000" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2015-01-14 09:02:02 +0000" MODIFIED_BY="[Empty name]">
<P>All review authors identified the trials comparing surgical repair versus selective surveillance for small AAAs.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2015-01-14 09:05:35 +0000" MODIFIED_BY="[Empty name]">
<P>Three members of the research team (GF, MAMM, BdG) abstracted the data, which other team members (DJB and JTP) cross-checked. The data collected on each trial included information on the participants (age and sex distribution, aneurysm size), the interventions (graft type, frequency of ultrasound surveillance), and the outcomes (as specified in <LINK TAG="SELECTION_CRITERIA" TYPE="SECTION">Criteria for considering studies for this review</LINK>).</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2015-01-14 09:02:08 +0000" MODIFIED_BY="[Empty name]">
<P>The review authors discussed each of the trials and agreed on their inclusion or exclusion based on the adequacy of the random allocation, attainment of adequate sample size, and completeness of follow-up. The nature of the interventions did not permit participants or observers to be blinded, and so this lack did not disqualify trials from inclusion. In addition, we assessed the risk of bias of the included studies using the 'Risk of bias' tool as described in the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).The following domains were assessed and judged to be at low risk of bias, high risk of bias, or unclear risk of bias: selection bias, performance and detection bias, attrition bias, reporting bias, and other sources of bias.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2015-01-14 09:02:14 +0000" MODIFIED_BY="[Empty name]">
<P>We estimated risk ratios (RR) (endovascular aneurysm repair (EVAR) only), hazard ratios (HR) (open repair only) and 95% CIs based on Mantel-Haenszel Chi<SUP>2</SUP> statistic to assess the efficacy of the intervention at one year (endovascular and open repair) and six years (open repair only) following randomisation. The HRs reported for open repair were estimated from a participant-level meta-analysis that was executed to summarize evidence from the <LINK REF="STD-UKSAT" TYPE="STUDY">UKSAT</LINK> and <LINK REF="STD-ADAM" TYPE="STUDY">ADAM</LINK> trials (<LINK REF="REF-Filardo--2013" TYPE="REFERENCE">Filardo 2013</LINK>; <LINK REF="REF-Filardo-2014" TYPE="REFERENCE">Filardo 2014</LINK>).</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2015-01-14 09:02:15 +0000" MODIFIED_BY="[Empty name]">
<P>Each participant with an AAA of diameter 4.0 cm to 5.5 cm who received immediate surgical repair versus routine ultrasound surveillance was the unit of analysis.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2012-01-31 23:25:39 +0000" MODIFIED_BY="[Empty name]">
<P>None of the studies included in this review used single or multiple imputation procedures to deal with missing data. However, the incidence of missing data was very low.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2015-01-14 09:06:17 +0000" MODIFIED_BY="[Empty name]">
<P>We assessed heterogeneity using the I<SUP>2 </SUP>statistic. We considered I<SUP>2</SUP> values of 50% or greater to indicate substantial heterogeneity. Moreover, we used a Chi<SUP>2</SUP> test to assess heterogeneity in the participant-level meta-analysis we executed to summarise evidence from the <LINK REF="STD-UKSAT" TYPE="STUDY">UKSAT</LINK> and <LINK REF="STD-ADAM" TYPE="STUDY">ADAM</LINK> trials. If we identified heterogeneity, we explored reasons for it.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2014-05-14 23:55:21 +0100" MODIFIED_BY="[Empty name]">
<P>All included studies published findings on the main study outcome of this review.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2015-01-14 09:02:26 +0000" MODIFIED_BY="[Empty name]">
<P>RRs (EVAR only), HRs (open repair only), and 95% CIs based on Mantel-Haenszel Chi<SUP>2</SUP> statistic were estimated. We calculated the RR summary estimates by employing a fixed-effect model meta-analyses approach. We estimated HRs from a participant-level meta-analysis we executed to summarise evidence from the <LINK REF="STD-UKSAT" TYPE="STUDY">UKSAT</LINK> and <LINK REF="STD-ADAM" TYPE="STUDY">ADAM</LINK> trials (<LINK REF="REF-Filardo--2013" TYPE="REFERENCE">Filardo 2013</LINK>; <LINK REF="REF-Filardo-2014" TYPE="REFERENCE">Filardo 2014</LINK>).</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2015-01-14 09:02:28 +0000" MODIFIED_BY="[Empty name]">
<P>We analysed and presented separately studies comparing immediate EVAR to surveillance and studies comparing immediate open repair to surveillance. Given the differences in surgical techniques, we did not estimate the overall effect associated with immediate repair irrespective of the type of surgery compared to surveillance. Accordingly, we executed tests for heterogeneity for each meta-analysis, one reporting on immediate EVAR versus surveillance and one reporting on immediate open repair versus surveillance.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2015-01-14 09:02:30 +0000" MODIFIED_BY="[Empty name]">
<P>We included all relevant published studies in this review; accordingly, we did not carry out a sensitivity analysis.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2015-01-14 09:06:39 +0000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2015-01-14 09:06:21 +0000" MODIFIED_BY="[Empty name]">
<P>See <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>.</P>
<SEARCH_RESULTS MODIFIED="2015-01-14 09:02:31 +0000" MODIFIED_BY="[Empty name]">
<P>We identified four relevant randomised controlled trials from the electronic searches (<LINK REF="STD-ADAM" TYPE="STUDY">ADAM</LINK>; <LINK REF="STD-CAESAR" TYPE="STUDY">CAESAR</LINK>; <LINK REF="STD-PIVOTAL" TYPE="STUDY">PIVOTAL</LINK>; <LINK REF="STD-UKSAT" TYPE="STUDY">UKSAT</LINK>) and one from personal communication (<LINK REF="STD-Canadian-Trial" TYPE="STUDY">Canadian Trial</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2015-01-14 09:06:21 +0000" MODIFIED_BY="[Empty name]">
<P>See <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>. Four randomised controlled trials, the <LINK REF="STD-UKSAT" TYPE="STUDY">UKSAT</LINK>, <LINK REF="STD-ADAM" TYPE="STUDY">ADAM</LINK>, <LINK REF="STD-CAESAR" TYPE="STUDY">CAESAR</LINK>, and <LINK REF="STD-PIVOTAL" TYPE="STUDY">PIVOTAL</LINK> trials, fulfilled the criteria for consideration in the present review. We used results from analyses of pooled participant-level data from the <LINK REF="STD-UKSAT" TYPE="STUDY">UKSAT</LINK> and <LINK REF="STD-ADAM" TYPE="STUDY">ADAM</LINK> trials in the comparison of immediate open repair to selective surveillance (<LINK REF="REF-Filardo--2013" TYPE="REFERENCE">Filardo 2013</LINK>; <LINK REF="REF-Filardo-2014" TYPE="REFERENCE">Filardo 2014</LINK>).</P>
<P>All four trials enrolled people with small (4.0 cm to 5.5 cm) non-tender, asymptomatic AAAs and who were considered fit for surgery. The trials excluded people who were considered unfit for surgery, had symptoms associated with the aneurysm, were unable to attend the follow-up visit, or were unable to give informed consent. The <LINK REF="STD-ADAM" TYPE="STUDY">ADAM</LINK> study further excluded people who had received a revascularization procedure within three months of enrolment, had a myocardial infarction within six months of enrolment, or were expected to survive less than five years because of invasive cancer or another life-threatening disease. The <LINK REF="STD-CAESAR" TYPE="STUDY">CAESAR</LINK> trial, besides excluding those people not anatomically suitable for endovascular repair, further excluded people who had severe co-morbidities or a suprarenal or thoracic aorta equal to or greater than 4.0 cm in diameter, or that needed urgent repair. The <LINK REF="STD-PIVOTAL" TYPE="STUDY">PIVOTAL</LINK> study further excluded people who had had an abdominal or thoracic repair, an aneurysm originating equal to or less than 1.0 cm from the most distal main renal artery, life expectancy of less than 3 years, Society for Vascular Surgery score greater than 2 with the exception of age and controlled hypertension, baseline serum creatinine level greater than 2.5 mg/dL, or when the person did not meet the indications for use of the endograft device.</P>
<P>Lastly, age inclusion criteria were 50 to 79 years, 50 to 79 years, 40 to 90 years, and 60 to 76 years for the <LINK REF="STD-ADAM" TYPE="STUDY">ADAM</LINK>, <LINK REF="STD-CAESAR" TYPE="STUDY">CAESAR</LINK>, <LINK REF="STD-PIVOTAL" TYPE="STUDY">PIVOTAL</LINK>, and <LINK REF="STD-UKSAT" TYPE="STUDY">UKSAT</LINK> studies, respectively. Despite the relatively wider age range eligible for inclusion in the <LINK REF="STD-ADAM" TYPE="STUDY">ADAM</LINK>, <LINK REF="STD-CAESAR" TYPE="STUDY">CAESAR</LINK>, and <LINK REF="STD-PIVOTAL" TYPE="STUDY">PIVOTAL</LINK> trials, the majority of the participants fell within the same age range as the <LINK REF="STD-UKSAT" TYPE="STUDY">UKSAT</LINK> trial: 88%, approximately 70%, and approximately 70%, respectively. This is perhaps unsurprising given that AAA prevalence is much higher in older age groups.</P>
<P>Study designs were similar, with participants randomly allocated to either immediate surgery or selective surveillance. In the four trials, most participants assigned to the immediate-surgery group received endovascular or standard open repair within six weeks of randomisation. Likewise, in all four trials, participants assigned to selective surveillance were followed, without repair, at regular intervals (at minimum once every six months), and surgery was performed within six weeks if a) the aneurysm reached 5.5 cm in diameter; or b) the aneurysm enlarged by a minimum of 0.7 cm in six months (<LINK REF="STD-ADAM" TYPE="STUDY">ADAM</LINK>), 1.0 cm in one year (<LINK REF="STD-UKSAT" TYPE="STUDY">UKSAT</LINK>), greater than 1.0 cm in one year (<LINK REF="STD-CAESAR" TYPE="STUDY">CAESAR</LINK>), or a minimum of 0.5 cm between two six-month assessments (<LINK REF="STD-PIVOTAL" TYPE="STUDY">PIVOTAL</LINK>); or c) the aneurysm became symptomatic. Adherence to assigned treatment was very high across the four trials (<LINK REF="STD-UKSAT" TYPE="STUDY">UKSAT</LINK> had the lowest adherence rate at 92.6%), and at the end of the trials, mortality status was ascertained in 100% (<LINK REF="STD-ADAM" TYPE="STUDY">ADAM</LINK>; <LINK REF="STD-PIVOTAL" TYPE="STUDY">PIVOTAL</LINK>; <LINK REF="STD-UKSAT" TYPE="STUDY">UKSAT</LINK>) and 98% (<LINK REF="STD-CAESAR" TYPE="STUDY">CAESAR</LINK>) of participants. Approximately 62%, 48%, 31%, and 75% of the participants in the selective-surveillance group of the <LINK REF="STD-ADAM" TYPE="STUDY">ADAM</LINK>, <LINK REF="STD-CAESAR" TYPE="STUDY">CAESAR</LINK>, <LINK REF="STD-PIVOTAL" TYPE="STUDY">PIVOTAL</LINK>, and <LINK REF="STD-UKSAT" TYPE="STUDY">UKSAT</LINK> studies, respectively, eventually underwent aneurysm repair.<BR/>
</P>
<P>In total, 3314 participants with asymptomatic AAAs of antero-posterior diameter 4.0 cm to 5.5 cm were randomised to immediate surgery (n = 1680: 569 in <LINK REF="STD-ADAM" TYPE="STUDY">ADAM</LINK>, 182 in <LINK REF="STD-CAESAR" TYPE="STUDY">CAESAR</LINK>, 366 in <LINK REF="STD-PIVOTAL" TYPE="STUDY">PIVOTAL</LINK>, and 563 in <LINK REF="STD-UKSAT" TYPE="STUDY">UKSAT</LINK>; 50.7%) or routine ultrasound or computed tomography surveillance every six months (three months if diameter 5.0 cm to 5.5 cm in <LINK REF="STD-ADAM" TYPE="STUDY">ADAM</LINK> and <LINK REF="STD-UKSAT" TYPE="STUDY">UKSAT</LINK>) (n = 1634: 567 in <LINK REF="STD-ADAM" TYPE="STUDY">ADAM</LINK>, 178 in <LINK REF="STD-CAESAR" TYPE="STUDY">CAESAR</LINK>, 362 in <LINK REF="STD-PIVOTAL" TYPE="STUDY">PIVOTAL</LINK>, and 527 in <LINK REF="STD-UKSAT" TYPE="STUDY">UKSAT</LINK>; 49.3%). The primary outcome of the included studies was all-cause mortality and secondary outcomes were AAA-related death, morbidity and quality of life. Follow-up for vital status ranged from 3.5 to 8.0 years (mean 4.9 years) in the <LINK REF="STD-ADAM" TYPE="STUDY">ADAM</LINK> trial; median 32.4 months (interquartile range (IQR) 21.0 to 44.1) in the immediate endovascular repair group and 30.9 (IQR 18.3 to 45.3) in the surveillance group in the <LINK REF="STD-CAESAR" TYPE="STUDY">CAESAR</LINK> trial; 20 plus or minus 12 months (range 0 to 41 months) in the <LINK REF="STD-PIVOTAL" TYPE="STUDY">PIVOTAL</LINK> trial; and up to 12 years (range 8 to 12 years, mean 10 years) in the <LINK REF="STD-UKSAT" TYPE="STUDY">UKSAT</LINK> trial.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2015-01-14 09:05:35 +0000" MODIFIED_BY="[Empty name]">
<P>The trial that did not fulfil the criteria for consideration was the <LINK REF="STD-Canadian-Trial" TYPE="STUDY">Canadian Trial</LINK>, which ended early because of inadequate recruitment and was not sufficiently complete for inclusion in this review (Cole CW, personal communication, 1998). See <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2015-01-14 09:06:34 +0000" MODIFIED_BY="[Empty name]">
<P>See <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK> for the 'Risk of bias' summary.</P>
<ALLOCATION MODIFIED="2014-10-23 12:30:32 +0100" MODIFIED_BY="[Empty name]">
<P>The methods of randomisation of the included studies ensured good balance across study groups. Adherence to assigned treatment was high, with the lowest adherence rate across the four trials at 92.6% (<LINK REF="STD-ADAM" TYPE="STUDY">ADAM</LINK>; <LINK REF="STD-CAESAR" TYPE="STUDY">CAESAR</LINK>; <LINK REF="STD-PIVOTAL" TYPE="STUDY">PIVOTAL</LINK>; <LINK REF="STD-UKSAT" TYPE="STUDY">UKSAT</LINK>). Risk of allocation bias was very low.</P>
</ALLOCATION>
<BLINDING MODIFIED="2015-01-14 09:02:57 +0000" MODIFIED_BY="[Empty name]">
<P>The nature of the interventions did not permit the blinding of participants or observers, so we judged each included trial as being at an unclear risk of performance and detection bias (<LINK REF="STD-ADAM" TYPE="STUDY">ADAM</LINK>; <LINK REF="STD-CAESAR" TYPE="STUDY">CAESAR</LINK>; <LINK REF="STD-PIVOTAL" TYPE="STUDY">PIVOTAL</LINK>; <LINK REF="STD-UKSAT" TYPE="STUDY">UKSAT</LINK>).</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2015-01-14 09:02:59 +0000" MODIFIED_BY="[Empty name]">
<P>We ascertained mortality status in 100% (<LINK REF="STD-ADAM" TYPE="STUDY">ADAM</LINK>; <LINK REF="STD-PIVOTAL" TYPE="STUDY">PIVOTAL</LINK>; <LINK REF="STD-UKSAT" TYPE="STUDY">UKSAT</LINK>) and 98% (<LINK REF="STD-CAESAR" TYPE="STUDY">CAESAR</LINK>) of participants. Moreover, the included studies experienced low loss to follow-up rates. Risk of attrition bias was very low.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2015-01-14 09:02:59 +0000" MODIFIED_BY="[Empty name]">
<P>All included studies published findings on the primary outcome measures of this review and reported on the outcomes pre-planned in their protocols (<LINK REF="STD-ADAM" TYPE="STUDY">ADAM</LINK>; <LINK REF="STD-CAESAR" TYPE="STUDY">CAESAR</LINK>; <LINK REF="STD-PIVOTAL" TYPE="STUDY">PIVOTAL</LINK>; <LINK REF="STD-UKSAT" TYPE="STUDY">UKSAT</LINK>). Risk of selective reporting bias was very low.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2015-01-14 09:06:34 +0000" MODIFIED_BY="[Empty name]">
<P>The <LINK REF="STD-CAESAR" TYPE="STUDY">CAESAR</LINK> trial was originally funded by Cook Medical. In December 2006, during the enrolment phase of the trial, Cook Medical withdrew sponsorship, and the trial continued as full spontaneous research. According to the <LINK REF="STD-CAESAR" TYPE="STUDY">CAESAR</LINK> study team, the design, data collection, data analysis, data interpretation, and writing of reports regarding the trial were at all times conducted independently from the sponsor. However, we could not exclude a possible conflict of interest in the <LINK REF="STD-CAESAR" TYPE="STUDY">CAESAR</LINK> trial given that the sponsor of the study, Cook Medical, withdrew. The <LINK REF="STD-PIVOTAL" TYPE="STUDY">PIVOTAL</LINK> trial was sponsored by Medtronic Vascular, who hold the <LINK REF="STD-PIVOTAL" TYPE="STUDY">PIVOTAL</LINK> trial study database. Two members of the <LINK REF="STD-PIVOTAL" TYPE="STUDY">PIVOTAL</LINK> research team who received funding from and were consultants for Medtronic declared conflicts of interest; a third member of the <LINK REF="STD-PIVOTAL" TYPE="STUDY">PIVOTAL</LINK> research team had previously been a consultant for Medtronic. The Vascular Surgery Academic Co-ordinating Center of the Cleveland Clinic was independently responsible for the conduct of the study and its analysis. Other potential sources of bias for the remaining trials included in this review were not identified and are therefore unclear.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2015-01-14 09:06:39 +0000" MODIFIED_BY="[Empty name]">
<P>In both the <LINK REF="STD-UKSAT" TYPE="STUDY">UKSAT</LINK> and <LINK REF="STD-ADAM" TYPE="STUDY">ADAM</LINK> studies, the 30-day operative mortality in the immediate-surgery group (5.5% <LINK REF="STD-UKSAT" TYPE="STUDY">UKSAT</LINK> and 2.1% <LINK REF="STD-ADAM" TYPE="STUDY">ADAM</LINK>) led to an early mortality disadvantage in this study group. The lower 30-day operative mortality rate observed in the <LINK REF="STD-ADAM" TYPE="STUDY">ADAM</LINK> trial was expected due to the more restrictive study inclusion and exclusion criteria of the trial and better lung and renal function of the participants.</P>
<P>In the <LINK REF="STD-UKSAT" TYPE="STUDY">UKSAT</LINK> study, the long-term mortality (follow-up range: 8 to 12 years, mean 10 years) was 63.9% in the immediate-surgery group and 67.3% in the surveillance group. The UKSAT investigators found no statistically significant difference in long-term survival between the immediate-surgery and surveillance groups (adjusted HR 0.88, 95% CI 0.75 to 1.02). However, the hazards were nonproportional among study groups, as revealed by the survival curves crossing at approximately the three-year mark; the risk associated with operative mortality in the immediate repair group resulted in an initial survival disadvantage for this study group compared to the selective-surveillance group. The estimated adjusted HRs were in the direction of greater benefit of immediate surgery for younger patients and those with larger aneurysms, but none of the tests for interaction was statistically significant.</P>
<P>At the end of the <LINK REF="STD-ADAM" TYPE="STUDY">ADAM</LINK> trial follow-up (range 3.5 to 8.0 years, mean 4.9 years), the observed mortalities in the immediate repair and the selective-surveillance groups were 25.1% and 21.5%, respectively. However, as in the <LINK REF="STD-UKSAT" TYPE="STUDY">UKSAT</LINK> study, the long-term survival was not statistically significantly different between study groups (adjusted HR 1.21, 95% CI 0.95 to 1.54). The authors did not report violation of the proportional hazard assumption. Study results showed a possible modification of effect with age and AAA size but, as in the <LINK REF="STD-UKSAT" TYPE="STUDY">UKSAT</LINK> study, none of the tests for interaction was significant. However, the analysis of the pooled participant-level data from the <LINK REF="STD-ADAM" TYPE="STUDY">ADAM</LINK> and <LINK REF="STD-UKSAT" TYPE="STUDY">UKSAT</LINK> trials demonstrated no significant difference in survival between immediate open repair and surveillance, regardless of patient age or aneurysm diameter (<LINK REF="REF-Filardo--2013" TYPE="REFERENCE">Filardo 2013</LINK>; <LINK REF="REF-Filardo-2014" TYPE="REFERENCE">Filardo 2014</LINK>).</P>
<P>In the <LINK REF="STD-CAESAR" TYPE="STUDY">CAESAR</LINK> and <LINK REF="STD-PIVOTAL" TYPE="STUDY">PIVOTAL</LINK> trials, the 30-day operative mortality in the immediate-surgery group (0.6% <LINK REF="STD-CAESAR" TYPE="STUDY">CAESAR</LINK> and 0.3% <LINK REF="STD-PIVOTAL" TYPE="STUDY">PIVOTAL</LINK>) led to an early disadvantage in terms of survival in this study group. The lower 30-day mortality rate observed in the <LINK REF="STD-CAESAR" TYPE="STUDY">CAESAR</LINK> and <LINK REF="STD-PIVOTAL" TYPE="STUDY">PIVOTAL</LINK> studies, compared to the <LINK REF="STD-UKSAT" TYPE="STUDY">UKSAT</LINK> and <LINK REF="STD-ADAM" TYPE="STUDY">ADAM</LINK> trials, was expected, due to the use of endovascular repair.</P>
<P>At the end of the <LINK REF="STD-CAESAR" TYPE="STUDY">CAESAR</LINK> trial follow-up (maximum: 54 months, median: 32.4 months), the estimated all-cause mortalities for the immediate-surgery group and the selective-surveillance groups were 14.5% and 10.1%, respectively. However, long-term survival was not statistically different between study groups (HR 0.76, 95% CI 0.30 to 1.93; P = 0.6). The authors did not report a violation of the proportional hazard assumption.</P>
<P>At the end of the <LINK REF="STD-PIVOTAL" TYPE="STUDY">PIVOTAL</LINK> trial follow-up (range 0 to 41 months, mean 20 plus or minus 12 months), the estimated all-cause mortalities for the immediate-surgery and selective-surveillance groups were both 4.1%, and long-term survival did not significantly differ between groups (HR 1.01, 95% CI 0.49 to 2.07; P = 0.98). The authors reported no evidence of nonproportional hazards between the two groups over time.</P>
<P>We performed meta-analyses of mortality at one year to assess the effect of endovascular aneurysm repair (<LINK REF="STD-CAESAR" TYPE="STUDY">CAESAR</LINK> and <LINK REF="STD-PIVOTAL" TYPE="STUDY">PIVOTAL</LINK> only) and up to six years to assess the effect of open repair (<LINK REF="STD-ADAM" TYPE="STUDY">ADAM</LINK> and <LINK REF="STD-UKSAT" TYPE="STUDY">UKSAT</LINK>). The meta-analysis regarding the efficacy of immediate endovascular repair revealed a non-significantly greater risk of mortality (RR 1.15, 95% CI 0.60 to 2.17; I<SUP>2 </SUP>= 0%) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>; <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>). Likewise, the analysis of pooled participant-level data from the <LINK REF="STD-UKSAT" TYPE="STUDY">UKSAT</LINK> and <LINK REF="STD-ADAM" TYPE="STUDY">ADAM</LINK> trials we conducted to assess mortality up to six years found no difference in survival between immediate open repair and surveillance (HR 0.99, 95% CI 0.83 to 1.18; Chi<SUP>2</SUP> test for interaction P = 0.92; <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>) (<LINK REF="REF-Filardo--2013" TYPE="REFERENCE">Filardo 2013</LINK>; <LINK REF="REF-Filardo-2014" TYPE="REFERENCE">Filardo 2014</LINK>). Additional analyses conducted using this pooled data set showed this lack of a statistically significant difference in survival persisted regardless of patient age (propensity-adjusted P = 0.61) or AAA diameter (propensity-adjusted P = 0.39) within the range of 4.0 cm to 5.5 cm (<LINK REF="REF-Filardo--2013" TYPE="REFERENCE">Filardo 2013</LINK>; <LINK REF="REF-Filardo-2014" TYPE="REFERENCE">Filardo 2014</LINK>).</P>
<P>In <LINK REF="STD-UKSAT" TYPE="STUDY">UKSAT</LINK>, quality of life was assessed using the 20-item Medical Outcomes Study short-form. At randomisation, quality of life was similar in the two groups, but immediate-surgery participants reported minor improvements in current health perceptions and less negative changes in bodily pain. In the <LINK REF="STD-ADAM" TYPE="STUDY">ADAM</LINK> trial, quality of life was assessed using the SF-36. The immediate-surgery and surveillance groups did not differ significantly for most SF-36 scales at most of the time points measured, but the immediate-surgery group scored significantly higher in general health (P &lt; 0.01), particularly during the first two years following randomisation, and lower in vitality (P &lt; 0.05). However, more participants became impotent after randomisation to immediate repair compared with surveillance (P &lt; 0.03), but this difference did not become apparent until more than one year after randomisation. Maximum activity level did not differ significantly between the two randomised groups, but decline over time was significantly greater in the immediate repair group (P &lt; 0.02). In the <LINK REF="STD-CAESAR" TYPE="STUDY">CAESAR</LINK> trial, comparable quality of life (SF-36) scores were seen in the immediate endovascular repair and surveillance groups at randomisation. At six months, the total SF-36 and the physical and mental domain scores were all significantly higher with respect to baseline in the immediate-repair group, while participants in the surveillance group scored lower. However, differences between the two groups diminished over time so that at the last assessment (one year or more after randomisation), there was no significant difference between immediate repair and surveillance (P = 0.25). The <LINK REF="STD-PIVOTAL" TYPE="STUDY">PIVOTAL</LINK> trial compared quality of life between the immediate endovascular repair and surveillance groups in the 710 participants who completed the EQ-5D instrument at baseline, 12 months, and 24 months. There were no statistically significant differences between the intervention groups at baseline on any of the EQ-5D domains, and no treatment-related differences were seen in either the quality-of-life domains or the utility score at 12 or 24 months follow-up. Immediate endovascular repair participants did report significantly lower (P = 0.03) visual analog scale scores at 12 months, but this difference did not persist at 24 months.</P>
<P>In <LINK REF="STD-UKSAT" TYPE="STUDY">UKSAT</LINK>, the mean health service costs per participant over the 4 to 6 years follow-up period postrandomisation were higher in the surgery than the surveillance group (GBP4978 versus GBP3914; difference GBP1064, 95% CI GBP796 to GBP1332). This estimate accounted for semi-annual surveillance visits, aneurysm repair, and any associated follow-up. For example, if surveillance was conducted only once per annum, the mean cost difference in favour of surveillance widened to GBP1256 (95% CI GBP990 to GBP1522). A 25% increase in cost of aneurysm repair further increased the difference, to GBP1636 (95% CI GBP1340 to GBP1932). The <LINK REF="STD-PIVOTAL" TYPE="STUDY">PIVOTAL</LINK> trial reported significantly greater total medical costs (including AAA-related office visits and imaging studies, AAA repair (endovascular device or open surgery), and other inpatient care (including secondary procedures, emergency department visits, other hospitalisations, and rehabilitation and skilled nursing facility care) in the immediate endovascular repair group at 6 months (USD33,471 versus USD5520; difference USD27,951, 95% CI USD25,156 to USD30,746), but greater total medical costs in the surveillance group in months 7 to 48 (USD40,592 versus USD15,197; difference USD25,395, 95% CI USD15,184 to USD35,605). These differences balanced out across the full 48 months studied such that there was no significant difference in total medical costs between the two interventions (USD48,669 in immediate endovascular repair versus USD46,112 in surveillance; difference USD2557, 95% CI -USD8043 to USD13,156). No cost data were available for the remaining two trials (<LINK REF="STD-ADAM" TYPE="STUDY">ADAM</LINK>; <LINK REF="STD-CAESAR" TYPE="STUDY">CAESAR</LINK>).</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2015-01-14 09:06:50 +0000" MODIFIED_BY="[Empty name]">
<P>The results from the four trials to date suggest no overall advantage to immediate repair for small AAA (<LINK REF="STD-ADAM" TYPE="STUDY">ADAM</LINK>; <LINK REF="STD-CAESAR" TYPE="STUDY">CAESAR</LINK>; <LINK REF="STD-PIVOTAL" TYPE="STUDY">PIVOTAL</LINK>; <LINK REF="STD-UKSAT" TYPE="STUDY">UKSAT</LINK>). Furthermore, the more recent trials focused on the efficacy of endovascular repair and still failed to show benefit (<LINK REF="STD-CAESAR" TYPE="STUDY">CAESAR</LINK>; <LINK REF="STD-PIVOTAL" TYPE="STUDY">PIVOTAL</LINK>), and analysis of the pooled participant-level data from the earlier open-repair trials showed that the lack of any treatment-related survival benefit was consistent across all participant ages and aneurysm diameters within the small AAA range (<LINK REF="REF-Filardo--2013" TYPE="REFERENCE">Filardo 2013</LINK>; <LINK REF="REF-Filardo-2014" TYPE="REFERENCE">Filardo 2014</LINK>). Thus, the currently available evidence supports neither immediate open nor immediate endovascular repair of small AAAs. Our results affirm the Society for Vascular Surgery's strong recommendation in favour of surveillance for people with a fusiform AAA of 4.0 cm to 5.4 cm (<LINK REF="REF-Chaikof-2009" TYPE="REFERENCE">Chaikof 2009</LINK>). While the development of endovascular technology offers a significantly reduced operative mortality compared to open surgery and better short-term survival in general (<LINK REF="REF-Lederle-2009" TYPE="REFERENCE">Lederle 2009</LINK>; <LINK REF="REF-Prinssen-2004" TYPE="REFERENCE">Prinssen 2004</LINK>; <LINK REF="REF-United-Kingdom-EVAR-Trial-Investigators-2010" TYPE="REFERENCE">United Kingdom EVAR Trial Investigators 2010</LINK>), its efficacy is limited by high rates of re-operation for complications unique to endovascular repair over longer follow-up, including stent migration, stent wire fracture, metal fatigue, graft insertion site problems, and endoleak (<LINK REF="REF-Becquemin-2011" TYPE="REFERENCE">Becquemin 2011</LINK>; <LINK REF="REF-De-Bruin-2010" TYPE="REFERENCE">De Bruin 2010</LINK>; <LINK REF="REF-EVAR-Trial-Participants-2005" TYPE="REFERENCE">EVAR Trial Participants 2005</LINK>; <LINK REF="REF-Wilt-2006" TYPE="REFERENCE">Wilt 2006</LINK>). For small AAA in particular, immediate endovascular repair does not appear to be superior to surveillance (see <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>, which shows a non-significant benefit in favour of surveillance), and its use could expose patients to unnecessary risk and ultimately higher healthcare costs (<LINK REF="REF-Ballard-2012" TYPE="REFERENCE">Ballard 2012</LINK>). Likewise, <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK> shows that immediate open repair offers no superior outcomes compared to surveillance for people with small AAAs.</P>
<P>However, it should be kept in mind that the results presented here all derive from randomised controlled trial settings which, particularly for the surveillance group, may not reflect current practice in terms of either the resources available for care or the patient compliance with follow-up schedules that can be expected. Thus, while we can conclude that there is no significance difference in <I>efficacy</I> between immediate repair and surveillance in small AAAs, the question regarding <I>effectiveness</I> requires further investigation, particularly for small AAAs approaching the 5.5 cm cut-off, where a recent meta-analysis suggests an eight-month surveillance interval is needed to adequately manage the risk of expansion past 5.5 cm (<LINK REF="REF-Bown-2013" TYPE="REFERENCE">Bown 2013</LINK>), and poor compliance with surveillance could tip the balance on patients' risks towards greater benefit with immediate repair. As there is currently no registry containing surveillance data for small AAAs, a large, prospective, population-based comparative effectiveness study is needed (<LINK REF="REF-Ballard-2012" TYPE="REFERENCE">Ballard 2012</LINK>).</P>
<P>Future research should include investigating the possible differences in quality of life between the various management strategies available for small AAA, taking into account that these might differ by age, and the evidence that moderate exercise (rather than the strict limitation on physical activity previously advised for people with unrepaired small AAA) benefits patients under surveillance (<LINK REF="REF-Myers-2010" TYPE="REFERENCE">Myers 2010</LINK>; <LINK REF="REF-Tew-2012" TYPE="REFERENCE">Tew 2012</LINK>). Additionally, the risks of rupture and those associated with repair need to be elucidated in women. There is some evidence that these risks differ in men and women with AAA (<LINK REF="REF-Abedi-2009" TYPE="REFERENCE">Abedi 2009</LINK>; <LINK REF="REF-Lo-2013" TYPE="REFERENCE">Lo 2013</LINK>; <LINK REF="REF-McPhee-2007" TYPE="REFERENCE">McPhee 2007</LINK>; <LINK REF="REF-Mehta-2012" TYPE="REFERENCE">Mehta 2012</LINK>; <LINK REF="STD-UKSAT" TYPE="STUDY">UKSAT</LINK>), but studies to date have generally included very few women, and, in the absence of sufficient data to rigorously examine the competing risks and the timing of intervention in women (<LINK REF="REF-Rudarakanchana-2013" TYPE="REFERENCE">Rudarakanchana 2013</LINK>), recommendations for management in women remain a 'best guess' guided largely by the evidence available for men.</P>
<P>Establishing optimal treatment guidelines for people with small AAAs becomes even more relevant to improving public health and patient outcomes when the likelihood of increased AAA screening in the future is taken into account. The evidence from three randomised population screening trials, summarised in a Cochrane review, shows the benefits of screening older men for AAA (<LINK REF="REF-Cosford-2007" TYPE="REFERENCE">Cosford 2007</LINK>). A national screening programme for all men aged 65 years and older has started in the United Kingdom (<LINK REF="REF-UK-Screening" TYPE="REFERENCE">UK Screening</LINK>), and the U.S. Preventive Services Task Force (USPSTF) recommends AAA screening for men aged 65 to 75 years who have ever smoked (<LINK REF="REF-U.S.-Preventive-Task-Force" TYPE="REFERENCE">U.S. Preventive Task Force</LINK>). The Society for Vascular Surgery has also recommended screening of all men aged 60 to 85 years for AAA; women aged 60 to 85 years with cardiovascular risk factors; and men and women aged 50 years and older with a family history of AAA (<LINK REF="REF-Kent-2004" TYPE="REFERENCE">Kent 2004</LINK>). These recommendations are based on evidence that screening for AAA and repair of large AAAs (5.5 cm or more in diameter) leads to decreased AAA-specific mortality. However, the USPSTF also indicates that there is possible evidence of harms of screening and immediate treatment, including an increased number of surgeries with associated clinically significant morbidity and mortality and short-term psychological harms (<LINK REF="REF-U.S.-Preventive-Task-Force" TYPE="REFERENCE">U.S. Preventive Task Force</LINK>). These harms are of most concern for people with aneurysms in the 4.0 cm to 5.5 cm AAA size range, for whom current treatment guidelines are ambiguous.</P>
<SUMMARY_OF_RESULTS MODIFIED="2015-01-14 09:04:03 +0000" MODIFIED_BY="[Empty name]">
<P>Findings from this review indicate that there was no survival advantage with immediate repair compared to selective surveillance in people with asymptomatic aneurysms sized 4.0 cm to 5.5 cm in diameter. Results from the <LINK REF="STD-UKSAT" TYPE="STUDY">UKSAT</LINK>, <LINK REF="STD-ADAM" TYPE="STUDY">ADAM</LINK>, <LINK REF="STD-CAESAR" TYPE="STUDY">CAESAR</LINK>, and <LINK REF="STD-PIVOTAL" TYPE="STUDY">PIVOTAL</LINK> trials showed no significant differences in survival between the study treatment groups; the analysis of the pooled participant-level data from the <LINK REF="STD-ADAM" TYPE="STUDY">ADAM</LINK> and <LINK REF="STD-UKSAT" TYPE="STUDY">UKSAT</LINK> studies showed that this held true regardless of participant age or AAA diameter for open repair (<LINK REF="REF-Filardo--2013" TYPE="REFERENCE">Filardo 2013</LINK>; <LINK REF="REF-Filardo-2014" TYPE="REFERENCE">Filardo 2014</LINK>). In the absence of long-term, participant-level data for the <LINK REF="STD-PIVOTAL" TYPE="STUDY">PIVOTAL</LINK> and <LINK REF="STD-CAESAR" TYPE="STUDY">CAESAR</LINK> trials, we cannot draw firm conclusions about the long-term effects of immediate endovascular repair. However, findings to date suggest no advantage to immediate surgery for small AAA, and the currently available evidence supports neither immediate open nor immediate endovascular repair of small AAAs. The Society for Vascular Surgery guidelines strongly recommend surveillance for people with a fusiform AAA of 4.0 cm to 5.4 cm (<LINK REF="REF-Chaikof-2009" TYPE="REFERENCE">Chaikof 2009</LINK>).</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2015-01-14 09:04:07 +0000" MODIFIED_BY="[Empty name]">
<P>This review was based on all trials to date that were suitable for inclusion. However, one limitation of the present review is the low proportion of women and non-white races in the trials. The gender imbalance is exacerbated by the late onset of the disease in women and by the approximately three times higher prevalence of AAA in men than in women, and the black race has been identified as having a strong negative association with AAA (<LINK REF="REF-Lederle-1997" TYPE="REFERENCE">Lederle 1997</LINK>; <LINK REF="REF-Lederle-2000" TYPE="REFERENCE">Lederle 2000</LINK>). Thus, while it is indisputable that the study results might be difficult to generalise to women and non-white men, this review provides critical data that can benefit the population with the highest prevalence of AAA and, therefore, the vast majority of people with AAA. Future research regarding the management of small AAA should focus on minorities and women, as data regarding these populations are lacking. In particular, future research should assess whether the AAA-management recommendations, which are based on studies in which women are underrepresented, are applicable to women given their smaller body frames and, therefore, smaller abdominal aortas. This is critical given the evidence that risk of rupture, risks associated with repair, and progression of disease may differ between men and women (<LINK REF="REF-Abedi-2009" TYPE="REFERENCE">Abedi 2009</LINK>; <LINK REF="REF-Brown-2003" TYPE="REFERENCE">Brown 2003</LINK>; <LINK REF="REF-Lo-2013" TYPE="REFERENCE">Lo 2013</LINK>; <LINK REF="REF-McPhee-2007" TYPE="REFERENCE">McPhee 2007</LINK>; <LINK REF="REF-Mehta-2012" TYPE="REFERENCE">Mehta 2012</LINK>; <LINK REF="REF-RESCAN-Collaborators-2013" TYPE="REFERENCE">RESCAN Collaborators 2013</LINK>; <LINK REF="STD-UKSAT" TYPE="STUDY">UKSAT</LINK>).</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2015-01-14 09:04:08 +0000" MODIFIED_BY="[Empty name]">
<P>The <LINK REF="STD-UKSAT" TYPE="STUDY">UKSAT</LINK>, <LINK REF="STD-ADAM" TYPE="STUDY">ADAM</LINK>, <LINK REF="STD-CAESAR" TYPE="STUDY">CAESAR</LINK>, and <LINK REF="STD-PIVOTAL" TYPE="STUDY">PIVOTAL</LINK> trials were very similar in design and, more importantly, were all well-conducted studies. All relevant studies were identified and included in this review. Moreover, all relevant data were obtained. In summary, besides the possible bias deriving from the conflicts of interest regarding the <LINK REF="STD-CAESAR" TYPE="STUDY">CAESAR</LINK> and <LINK REF="STD-PIVOTAL" TYPE="STUDY">PIVOTAL</LINK> trials, the quality of evidence summarised in this review is high.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2015-01-14 09:05:35 +0000" MODIFIED_BY="[Empty name]">
<P>Three members of the research team (GF, MAMM, BdG) independently abstracted the data, which were cross-checked by other team members (DJB and JTP). To further reduce bias, the role of JTP (trialist in the <LINK REF="STD-UKSAT" TYPE="STUDY">UKSAT</LINK> study and author in the present review) in abstracting the data was limited to cross-checking the information abstracted.</P>
<P>Strengths of the present review regarding potential biases are: 1) all relevant studies were identified and included in the review; 2) all the studies included in the review had very similar designs and methods; 3) relevant data for all studies were obtained; and 4) all the studies included in the review shared the same main primary outcome, and this outcome is the outcome of interest for this review too. However as reported, we cannot exclude possible bias deriving from the conflicts of interest identified in the <LINK REF="STD-CAESAR" TYPE="STUDY">CAESAR</LINK> and <LINK REF="STD-PIVOTAL" TYPE="STUDY">PIVOTAL</LINK> trials.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2014-10-23 12:36:36 +0100" MODIFIED_BY="[Empty name]">
<P>To our knowledge, this is the only systematic review published to date on this topic.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2015-01-14 09:04:14 +0000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2015-01-14 09:04:14 +0000" MODIFIED_BY="[Empty name]">
<P>The current evidence supports delaying the timing of AAA repair until the aneurysm reaches 5.5 cm in diameter. Findings from the four trials to date suggest no advantage to immediate repair of small AAAs, irrespective of whether open or endovascular repair is used. The results of the analysis of the pooled participant-level data <LINK REF="STD-ADAM" TYPE="STUDY">ADAM</LINK> and <LINK REF="STD-UKSAT" TYPE="STUDY">UKSAT</LINK> trials show that for open repair, this remains consistent, regardless of participant age or AAA diameter. Unfortunately, long-term data from the two trials investigating endovascular repair are not available, so we can only draw firm conclusions regarding outcomes after the first few years for open repair.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2015-01-14 09:04:14 +0000" MODIFIED_BY="[Empty name]">
<P>Future research needs to move away from the &#8220;procedure as a solution&#8221; focus that has dominated AAA research and management to date and focus on what remains unknown about the disease itself. Large, prospective, population-based studies are needed to investigate disease progression in relation to AAA morphology (including shape, size, location, volume, and ratio of healthy aorta to the aneurysm). An early focus of this work should be to determine whether AAA volume is superior to diameter as a measure of disease progression. Another important question is whether efficacy or effectiveness of the various treatment options (open repair, endovascular repair, and the emerging medical management options) differs based on AAA morphology. Finally, research regarding the risks related to and management of small AAAs in minorities and women is urgently needed, as data regarding these populations are lacking. In particular, future research should assess whether the AAA management recommendations, which are based on studies in which women are underrepresented, are applicable to women given their smaller body frames and, therefore, smaller abdominal aortas. </P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2015-01-14 09:04:15 +0000" MODIFIED_BY="[Empty name]">
<P>The review authors thank Briget da Graca for abstracting data from the two most recent publications included in this review, as well as for background research and writing in preparing this manuscript, and Gerry Fowkes for his contribution to previous versions of this review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2015-02-06 07:52:09 +0000" MODIFIED_BY="[Empty name]">
<P>JTP was a co-investigator in the <LINK REF="STD-UKSAT" TYPE="STUDY">UKSAT </LINK>study and DJB was a co-investigator of the <LINK REF="STD-ADAM" TYPE="STUDY">ADAM</LINK> trial.<BR/>
<BR/>GF: none known
<BR/>
JTP: none known
<BR/>
MAMM: none known<BR/>DJB: none known<BR/>
</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2015-01-14 09:04:16 +0000" MODIFIED_BY="[Empty name]">
<P>All review authors identified trials and agreed on their inclusion or exclusion, adequacy of randomisation, attainment of adequate sample size, and completeness of follow-up. For this update, two members of the research team (GF and BdG) abstracted the data, which were cross-checked by the remaining review authors.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2015-01-14 09:04:28 +0000" MODIFIED_BY="[Empty name]">
<P>We did not report the overall effect for the 30-day mortality in this review. Inherent within the comparison between immediate repair and surveillance with selective repair is the fact that early mortality is always lower in the surveillance group; participants in the immediate-repair group underwent a surgery that carries at least some risk of operative mortality (how great a risk depending on whether open or endovascular surgery was used) almost immediately after enrolment, while patients in the surveillance group were simply monitored. As such, 30-day mortality is not a measure of interest. However, since the 30-day mortality effects differed between the included studies, we did report these effects for each individual study in the descriptions of the included studies.</P>
<P>A second difference between this update of the review and the original protocol was the use of hazard ratios to describe one- and six-year survival for the <LINK REF="STD-ADAM" TYPE="STUDY">ADAM</LINK> and <LINK REF="STD-UKSAT" TYPE="STUDY">UKSAT</LINK>. We based this decision on the fact that, when we conducted this review, we had the participant-level data for these two studies and were able to pool these data to estimate the hazard ratios. Since we only had tabular data for the <LINK REF="STD-CAESAR" TYPE="STUDY">CAESAR</LINK> and <LINK REF="STD-PIVOTAL" TYPE="STUDY">PIVOTAL</LINK> trials, we could not estimate a hazard ratio for the one-year survival comparison between immediate endovascular repair and surveillance. As such, we estimated a risk ratio in this case.</P>
<P>For this update the term 'immediate' has replaced 'early' throughout the text, to be consistent with the trials' definition.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2015-01-14 09:05:35 +0000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2015-01-14 09:05:35 +0000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2015-01-14 09:05:35 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-ADAM" MODIFIED="2015-01-14 09:05:35 +0000" MODIFIED_BY="[Empty name]" NAME="ADAM" YEAR="">
<REFERENCE MODIFIED="2015-01-14 09:05:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Filardo G, Lederle FA, Ballard DJ, Hamilton C, da Graca B, Herrin J, et al</AU>
<TI>Effect of age on survival between open repair and surveillance for small abdominal aortic aneurysms</TI>
<SO>American Journal of Cardiology</SO>
<YR>2014</YR>
<VL>114</VL>
<NO>8</NO>
<PG>1281-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-10-09 09:46:57 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Filardo G, Lederle FA, Ballard DJ, Hamilton C, da Graca B, Herrin J, et al</AU>
<TI>Immediate open repair vs surveillance in patients with small abdominal aortic aneurysms: survival differences by aneurysm size</TI>
<SO>Mayo Clinic Proceedings</SO>
<YR>2013</YR>
<VL>88</VL>
<NO>9</NO>
<PG>910-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-10-18 12:02:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lederle FA, Johnson GR, Wilson SE, Acher CW, Ballard DJ, Littooy FN, et al</AU>
<TI>Quality of life, impotence, and activity level in a randomized trial of immediate repair versus surveillance of small abdominal aortic aneurysm</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>2003</YR>
<VL>38</VL>
<NO>4</NO>
<PG>745-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-14 09:05:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lederle FA, Johnson GR, Wilson SE, Chute EP, Hye RJ, Makaroun MS, et al; Aneurysm Detection and Management Veterans Affairs Cooperative Study Investigators</AU>
<TI>The aneurysm detection and management study screening programme: validation cohort and final results.</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2000</YR>
<VL>160</VL>
<NO>10</NO>
<PG>1425-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-14 09:05:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lederle FA, Johnson GR, Wilson SE, Chute EP, Littooy FN, Bandyk D, et al; Aneurysm Detection and Management (ADAM) Veterans Affairs Cooperative Study Group</AU>
<TI>Prevalence and associations of abdominal aortic aneurysm detected through screening.</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1997</YR>
<VL>126</VL>
<NO>6</NO>
<PG>441-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-14 09:05:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lederle FA, Johnson GR, Wilson SE, Gordon IL, Chute EP, Littooy FN, et al; The Aneurysm Detection and Management (ADAM) Veterans Affairs Cooperative Study Investigators</AU>
<TI>Relationship of age, gender, race, and body size to infrarenal aortic diameter.</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>1997</YR>
<VL>26</VL>
<NO>4</NO>
<PG>595-601</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-19 08:45:12 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lederle FA, Wilson SE, Johnson GR, Littooy FN, Acher C, Messina LM, et al</AU>
<TI>Design of the abdominal aortic Aneurysm Detection and Management Study</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>1994</YR>
<VL>20</VL>
<NO>2</NO>
<PG>296-303</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-14 08:32:03 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lederle FA, Wilson SE, Johnson GR, Reinke DB, Littooy FN, Acher CW, et al</AU>
<TI>Immediate repair compared with surveillance of small abdominal aortic aneurysms</TI>
<SO>New England Journal of Medicine</SO>
<YR>2002</YR>
<VL>346</VL>
<NO>19</NO>
<PG>1437-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-CAESAR" MODIFIED="2015-01-14 09:05:35 +0000" MODIFIED_BY="[Empty name]" NAME="CAESAR" YEAR="2011">
<REFERENCE MODIFIED="2012-01-31 12:26:11 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cao P, De Rango P, Verzini F, Parlani G, Romano L, Cieri E, for the CAESAR Trial Group</AU>
<TI>Comparison of Surveillance Versus Aortic Endografting for Small Aneurysm Repair (CAESAR): Results from a randomised trial</TI>
<SO>European Journal of Vascular and Endovascular Surgery</SO>
<YR>2011</YR>
<VL>41</VL>
<NO>1</NO>
<PG>13-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-14 09:05:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cao P; CAESAR Trial Collaborators</AU>
<TI>Comparison of Surveillance vs Aortic Endografting for Small Aneurysm Repair (CAESAR) trial: study design and progress</TI>
<SO>European Journal of Vascular and Endovascular Surgery</SO>
<YR>2005</YR>
<VL>30</VL>
<NO>3</NO>
<PG>245-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-14 09:05:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Rango P, Verzini F, Parlani G, Cieri E, Romano L, Loschi D, et al</AU>
<TI>Quality of life in patients with small abdominal aortic aneurysm: the effect of early endovascular repair versus surveillance in the CAESAR trial</TI>
<SO>European Journal of Vascular and Endovascular Surgery</SO>
<YR>2011</YR>
<VL>41</VL>
<NO>3</NO>
<PG>324-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-14 09:05:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00118573</AU>
<TI>Comparison of Surveillance Versus Aortic Endografting for Small Aneurysm Repair</TI>
<SO>http://clinicaltrials.gov/ct/show/NCT00118573?order=1</SO>
<YR>(accessed 14 November 2011)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-PIVOTAL" MODIFIED="2015-01-14 09:05:35 +0000" MODIFIED_BY="[Empty name]" NAME="PIVOTAL" YEAR="2010">
<REFERENCE MODIFIED="2015-01-14 09:05:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eisenstein EL, Davidson-Ray L, Edwards R, Anstrom KJ, Ouriel K</AU>
<TI>Economic analysis of endovascular repair versus surveillance for patients with small abdominal aortic aneurysms</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>2013</YR>
<VL>58</VL>
<NO>2</NO>
<PG>302-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-14 09:05:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00444821</AU>
<TI>The (PIVOTAL) study</TI>
<SO>http://clinicaltrials.gov/ct/show/NCT00444821?order=1</SO>
<YR>(accessed 8 April 2014)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-10-26 17:59:49 +0100" MODIFIED_BY="Marlene Stewart" PRIMARY="NO" TYPE="OTHER">
<AU>Ouriel K, Clair DG, Kent CK, Zarins CK; PIVOTAL investigators</AU>
<TI>Endovascular repair compared with surveillance for patients with small abdominal aortic aneurysms</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>2009</YR>
<VL>50</VL>
<NO>2</NO>
<PG>449</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-10-26 18:01:46 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ouriel K, Clair DG, Kent KC, Zarins CK, for the Positive Impact of Endovascular Options for treating Aneurysms Early (PIVOTAL) Investigators</AU>
<TI>Endovascular repair compared with surveillance for patients with small abdominal aortic aneurysms</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>2010</YR>
<VL>51</VL>
<NO>5</NO>
<PG>1081-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-14 09:05:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ouriel K</AU>
<TI>The PIVOTAL study: a randomized comparison of endovascular repair versus surveillance in patients with smaller abdominal aortic aneurysms</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>2009</YR>
<VL>49</VL>
<NO>1</NO>
<PG>266-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-10-07 22:43:28 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-UKSAT" MODIFIED="2015-01-14 09:05:35 +0000" MODIFIED_BY="[Empty name]" NAME="UKSAT" YEAR="">
<REFERENCE MODIFIED="2015-01-14 09:05:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brown LC, Thompson SG, Greenhalgh RM, Powell JT; UK Small Aneurysm Trial Participants</AU>
<TI>Fit patients with small abdominal aortic aneurysms (AAAs) do not benefit from early intervention</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>2008</YR>
<VL>48</VL>
<NO>6</NO>
<PG>1375-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-10-09 09:46:06 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Filardo G, Lederle FA, Ballard DJ, Hamilton C, da Graca B, Herrin J, et al</AU>
<TI>Effect of age on survival between open repair and surveillance for small abdominal aortic aneurysms</TI>
<SO>American Journal of Cardiology</SO>
<YR>2014</YR>
<VL>1148</VL>
<NO>8</NO>
<PG>1281-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-14 09:05:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Filardo G, Lederle FA, Ballard DJ, Hamilton C, da Graca B, Herrin J, et al</AU>
<TI>Immediate open repair vs surveillance in patients with small abdominal aortic aneurysms: survival differences by aneurysm size</TI>
<SO>Mayo Clinic Proceedings</SO>
<YR>2013</YR>
<VL>88</VL>
<NO>9</NO>
<PG>910-19</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-05-29 16:23:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>The UK Small Aneurysm Trial Participants</AU>
<TI>Final 12-year follow-up of surgery versus surveillance in the UK Small Aneurysm Trial</TI>
<SO>British Journal of Surgery</SO>
<YR>2007</YR>
<VL>94</VL>
<NO>6</NO>
<PG>702-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-19 08:45:12 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>The UK Small Aneurysm Trial Participants</AU>
<TI>Health service costs and quality of life for early elective surgery or ultrasonographic surveillance for small abdominal aortic aneurysms</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>352</VL>
<NO>9141</NO>
<PG>1656-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-19 08:45:12 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>The UK Small Aneurysm Trial Participants</AU>
<TI>Mortality results for randomised controlled trial of early elective surgery or ultrasonographic surveillance for small abdominal aortic aneurysms</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>352</VL>
<NO>9141</NO>
<PG>1649-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-19 08:45:12 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>The UK Small Aneurysm Trial Participants</AU>
<TI>The UK Small Aneurysm Trial: design, methods and progress</TI>
<SO>European Journal of Vascular and Endovascular Surgery</SO>
<YR>1995</YR>
<VL>9</VL>
<NO>1</NO>
<PG>42-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-14 08:32:22 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>The United Kingdom Small Aneurysm Trial Participants</AU>
<TI>Long-term outcomes of immediate repair compared with surveillance of small abdominal aortic aneurysms</TI>
<SO>New England Journal of Medicine</SO>
<YR>2002</YR>
<VL>346</VL>
<NO>19</NO>
<PG>1445-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2015-01-14 09:05:35 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="UNPUB" ID="STD-Canadian-Trial" MODIFIED="2015-01-14 09:05:35 +0000" MODIFIED_BY="[Empty name]" NAME="Canadian Trial" YEAR="1998">
<REFERENCE MODIFIED="2015-01-14 09:05:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Cole CW</AU>
<TI>[personal communication]</TI>
<SO>Conversation with review authors Dr Ballard and Prof Powell</SO>
<YR>1998</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2011-10-07 21:46:43 +0100" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES MODIFIED="2011-10-11 17:59:56 +0100" MODIFIED_BY="[Empty name]"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2015-01-14 09:05:35 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2015-01-14 09:05:35 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Abedi-2009" MODIFIED="2015-01-14 09:05:35 +0000" MODIFIED_BY="[Empty name]" NAME="Abedi 2009" TYPE="JOURNAL_ARTICLE">
<AU>Abedi NN, Davenport DL, Xenos E, Sorial E, Minion DJ, Endean ED</AU>
<TI>Gender and 30-day outcome in patients undergoing endovascular aneurysm repair (EVAR): an analysis using the ACS NSQIP dataset</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>2009</YR>
<VL>50</VL>
<NO>3</NO>
<PG>486-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ballard-1992" MODIFIED="2015-01-14 09:05:35 +0000" MODIFIED_BY="[Empty name]" NAME="Ballard 1992" TYPE="BOOK">
<AU>Ballard DJ, Etchason JA, Hilborne LH, Campion ME, Kamberg CJ, Solomon DH, et al</AU>
<SO>Abdominal Aortic Aneurysm Surgery. A Literature Review and Ratings of Appropriateness and Necessity</SO>
<YR>1992</YR>
<PB>RAND</PB>
<CY>Santa Monica (CA)</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ballard-2012" MODIFIED="2012-01-13 12:21:45 +0000" MODIFIED_BY="[Empty name]" NAME="Ballard 2012" TYPE="JOURNAL_ARTICLE">
<AU>Ballard DJ, Filardo G, da Graca B, Powell JT</AU>
<TI>Clinical practice change requires more than comparative effectiveness evidence: abdominal aortic aneurysm management in the USA</TI>
<SO>Journal of Comparative Effectiveness Research</SO>
<YR>2012</YR>
<VL>1</VL>
<NO>1</NO>
<PG>31-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Becquemin-2011" MODIFIED="2012-01-31 12:27:59 +0000" MODIFIED_BY="[Empty name]" NAME="Becquemin 2011" TYPE="JOURNAL_ARTICLE">
<AU>Becquemin JP, Pillet JC, Lescalie F, Sapoval M, Goueffic Y, Lermusiaux P, et al</AU>
<TI>A randomized controlled trial of endovascular aneurysm repair versus open surgery for abdominal aortic aneurysms in low- to moderate-risk patients</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>2011</YR>
<VL>53</VL>
<NO>5</NO>
<PG>1167-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bernstein-1984" NAME="Bernstein 1984" TYPE="JOURNAL_ARTICLE">
<AU>Bernstein EF, Chan EL</AU>
<TI>Abdominal aortic aneurysm in high-risk patients. Outcome of selective management based on size and expansion rate</TI>
<SO>Annals of Surgery</SO>
<YR>1984</YR>
<VL>200</VL>
<NO>3</NO>
<PG>255-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bown-2013" MODIFIED="2015-01-14 09:05:35 +0000" MODIFIED_BY="[Empty name]" NAME="Bown 2013" TYPE="JOURNAL_ARTICLE">
<AU>Bown MJ, Sweeting MJ, Brown LC, Powell JT, Thompson SG</AU>
<TI>Surveillance intervals for small abdominal aortic aneurysms: a meta-analysis</TI>
<SO>JAMA</SO>
<YR>2013</YR>
<VL>309</VL>
<NO>8</NO>
<PG>806-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brown-2003" MODIFIED="2012-01-31 12:28:37 +0000" MODIFIED_BY="[Empty name]" NAME="Brown 2003" TYPE="JOURNAL_ARTICLE">
<AU>Brown PM, Zelt DT, Sobolev B</AU>
<TI>The risk of rupture in untreated aneurysms: the impact of size, gender, and expansion rate</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>2003</YR>
<VL>37</VL>
<NO>2</NO>
<PG>280-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chaikof-2009" MODIFIED="2014-04-30 20:42:41 +0100" MODIFIED_BY="[Empty name]" NAME="Chaikof 2009" TYPE="JOURNAL_ARTICLE">
<AU>Chaikof EL, Brewster DC, Dalman RL, Makaroun MS, Illig KA, Sicard GA, et al</AU>
<TI>The care of patients with an abdominal aortic aneurysm: the Society for Vascular Surgery practice guidelines</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>2009</YR>
<VL>50</VL>
<NO>4 Suppl</NO>
<PG>S2-49</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cosford-2007" MODIFIED="2011-10-19 09:58:37 +0100" MODIFIED_BY="[Empty name]" NAME="Cosford 2007" TYPE="COCHRANE_REVIEW">
<AU>Cosford PA, Leng GC, Thomas J</AU>
<TI>Screening for abdominal aortic aneurysm</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2011-10-19 09:58:37 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-10-19 09:58:37 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD002945.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-De-Bruin-2010" MODIFIED="2015-01-14 08:32:38 +0000" MODIFIED_BY="[Empty name]" NAME="De Bruin 2010" TYPE="JOURNAL_ARTICLE">
<AU>De Bruin JL, Baas AF, Buth J, Prinssen M, Verhoeven EL, Cuypers PW, et al</AU>
<TI>Long-term outcome of open or endovascular repair of abdominal aortic aneurysm</TI>
<SO>New England Journal of Medicine</SO>
<YR>2010</YR>
<VL>362</VL>
<NO>20</NO>
<PG>1881-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ernst-1993" MODIFIED="2015-01-14 08:32:43 +0000" MODIFIED_BY="[Empty name]" NAME="Ernst 1993" TYPE="JOURNAL_ARTICLE">
<AU>Ernst CB</AU>
<TI>Abdominal aortic aneurysm</TI>
<SO>New England Journal of Medicine</SO>
<YR>1993</YR>
<VL>328</VL>
<NO>16</NO>
<PG>1167-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-EVAR-Trial-Participants-2005" MODIFIED="2015-01-14 09:05:35 +0000" MODIFIED_BY="[Empty name]" NAME="EVAR Trial Participants 2005" TYPE="JOURNAL_ARTICLE">
<AU>EVAR Trial Participants</AU>
<TI>Endovascular aneurysm repair versus open repair in patients with abdominal aortic aneurysm (EVAR trial 1): randomised controlled trial</TI>
<SO>Lancet</SO>
<YR>2005</YR>
<VL>365</VL>
<NO>9478</NO>
<PG>2179-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Filardo--2013" MODIFIED="2015-01-14 09:05:35 +0000" MODIFIED_BY="[Empty name]" NAME="Filardo  2013" TYPE="JOURNAL_ARTICLE">
<AU>Filardo G, Lederle FA, Ballard DJ, Hamilton C, da Graca B, Herrin J, et al</AU>
<TI>Immediate open repair vs surveillance in patients with small abdominal aortic aneurysms: survival differences by aneurysm size</TI>
<SO>Mayo Clinic Proceedings</SO>
<YR>2013</YR>
<VL>88</VL>
<NO>9</NO>
<PG>910-19</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Filardo-2014" MODIFIED="2014-10-09 09:44:40 +0100" MODIFIED_BY="[Empty name]" NAME="Filardo 2014" TYPE="JOURNAL_ARTICLE">
<AU>Filardo G, Lederle FA, Ballard DJ, Hamilton C, da Graca B, Herrin J, et al</AU>
<TI>Effect of age on survival between open repair and surveillance for small abdominal aortic aneurysms</TI>
<SO>American Journal of Cardiology</SO>
<YR>2014</YR>
<VL>114</VL>
<NO>8</NO>
<PG>1281-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Golledge-2011" MODIFIED="2014-04-09 00:21:22 +0100" MODIFIED_BY="[Empty name]" NAME="Golledge 2011" TYPE="JOURNAL_ARTICLE">
<AU>Golledge J, Norman PE</AU>
<TI>Current status of medical management for abdominal aortic aneurysm</TI>
<SO>Atherosclerosis</SO>
<YR>2011</YR>
<VL>217</VL>
<NO>1</NO>
<PG>57-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hackam-2006" MODIFIED="2014-10-09 09:43:46 +0100" MODIFIED_BY="[Empty name]" NAME="Hackam 2006" TYPE="JOURNAL_ARTICLE">
<AU>Hackam DG, Thiruchelvam D, Redelmeier DA</AU>
<TI>Angiotensin-converting enzyme inhibitors and aortic rupture: a population-based case-control study</TI>
<SO>Lancet</SO>
<YR>2006</YR>
<VL>368</VL>
<NO>9536</NO>
<PG>659-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2012-01-31 12:29:22 +0000" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kent-2004" NAME="Kent 2004" TYPE="JOURNAL_ARTICLE">
<AU>Kent KC, Zwolak RM, Jaff MR, Hollenbeck ST, Thompson RW, Schermerhorn ML, et al</AU>
<TI>Screening for abdominal aortic aneurysm: a consensus statement</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>2004</YR>
<VL>39</VL>
<NO>1</NO>
<PG>267-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lederle-1996" NAME="Lederle 1996" TYPE="JOURNAL_ARTICLE">
<AU>Lederle FA</AU>
<TI>Risk of rupture of large abdominal aortic aneurysms. Disagreement among vascular surgeons</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1996</YR>
<VL>156</VL>
<NO>9</NO>
<PG>1007-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lederle-1997" MODIFIED="2015-01-14 09:05:35 +0000" MODIFIED_BY="[Empty name]" NAME="Lederle 1997" TYPE="JOURNAL_ARTICLE">
<AU>Lederle FA, Johnson GR, Wilson SE, Chute EP, Littooy FN, Bandyk D, et al; Aneurysm Detection and Management (ADAM) Veterans Affairs Cooperative Study Group</AU>
<TI>Prevalence and associations of abdominal aortic aneurysm detected through screening.</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1997</YR>
<VL>126</VL>
<NO>6</NO>
<PG>441-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lederle-1997a" MODIFIED="2015-01-14 09:05:35 +0000" MODIFIED_BY="[Empty name]" NAME="Lederle 1997a" TYPE="JOURNAL_ARTICLE">
<AU>Lederle FA, Johnson GR, Wilson SE, et al; The Aneurysm Detection and Management (ADAM) Veterans Affairs Cooperative Study Investigators</AU>
<TI>Relationship of age, gender, race, and body size to infrarenal aortic diameter.</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>1997</YR>
<VL>26</VL>
<NO>4</NO>
<PG>595-601</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lederle-2000" MODIFIED="2015-01-14 09:05:35 +0000" MODIFIED_BY="[Empty name]" NAME="Lederle 2000" TYPE="JOURNAL_ARTICLE">
<AU>Lederle FA, Johnson GR, Wilson SE, Chute EP, Hye RJ, Makaroun MS, et al; Aneurysm Detection and Management Veterans Affairs Cooperative Study Investigators</AU>
<TI>The aneurysm detection and management study screening program: validation cohort and final results.</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2000</YR>
<VL>160</VL>
<NO>10</NO>
<PG>1425-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lederle-2003" MODIFIED="2015-01-14 09:05:35 +0000" MODIFIED_BY="[Empty name]" NAME="Lederle 2003" TYPE="JOURNAL_ARTICLE">
<AU>Lederle FA, Nelson DB, Joseph AM</AU>
<TI>Smokers' relative risk for aortic aneurysm compared with other smoking-related diseases: a systematic review</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>2003</YR>
<VL>38</VL>
<NO>2</NO>
<PG>329-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lederle-2009" MODIFIED="2012-01-13 12:26:20 +0000" MODIFIED_BY="[Empty name]" NAME="Lederle 2009" TYPE="JOURNAL_ARTICLE">
<AU>Lederle FA, Freischlag JA, Kyriakides TC, Padberg Jr FT, Matsumura JS, Kohler TR</AU>
<TI>Outcomes following endovascular vs open repair of abdominal aortic aneurysm: a randomized trial</TI>
<SO>JAMA</SO>
<YR>2009</YR>
<VL>302</VL>
<NO>14</NO>
<PG>1535-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lo-2013" MODIFIED="2014-10-09 09:42:45 +0100" MODIFIED_BY="[Empty name]" NAME="Lo 2013" TYPE="JOURNAL_ARTICLE">
<AU>Lo RC, Bensley RP, Hamdan AD, Wyers M, Adams JE, Schermerhorn ML</AU>
<TI>Gender differences in abdominal aortic aneurysm presentation, repair, and mortality in the Vascular Study Group of New England</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>2013</YR>
<VL>57</VL>
<NO>5</NO>
<PG>1261-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McPhee-2007" MODIFIED="2015-01-14 09:05:35 +0000" MODIFIED_BY="[Empty name]" NAME="McPhee 2007" TYPE="JOURNAL_ARTICLE">
<AU>McPhee JT, Hill JS, Eslami MH</AU>
<TI>The impact of gender on presentation, therapy, and mortality of abdominal aortic aneurysm in the United States, 2001-2004</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>2007</YR>
<VL>45</VL>
<NO>5</NO>
<PG>891-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mehta-2012" MODIFIED="2014-10-09 09:42:40 +0100" MODIFIED_BY="[Empty name]" NAME="Mehta 2012" TYPE="JOURNAL_ARTICLE">
<AU>Mehta M, Byrne WJ, Robinson H, Roddy SP, Paty PS, Kreienberg PB, et al</AU>
<TI>Women derive less benefit from elective endovascular aneurysm repair than men</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>2012</YR>
<VL>55</VL>
<NO>4</NO>
<PG>906-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mosorin-2008" MODIFIED="2014-10-09 09:41:38 +0100" MODIFIED_BY="[Empty name]" NAME="Mosorin 2008" TYPE="JOURNAL_ARTICLE">
<AU>Mosorin M, Niemela E, Heikkinen J, Lahtinen J, Tiozzo V, Satta J, et al</AU>
<TI>The use of statins and fate of small abdominal aortic aneurysms</TI>
<SO>Interactive Cardiovascular and Thoracic Surgery</SO>
<YR>2008</YR>
<VL>7</VL>
<NO>4</NO>
<PG>578-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Myers-2010" MODIFIED="2015-01-14 09:05:35 +0000" MODIFIED_BY="[Empty name]" NAME="Myers 2010" TYPE="JOURNAL_ARTICLE">
<AU>Myers JN, White JJ, Narasimhan B, Dalman RL</AU>
<TI>Effects of exercise training in patients with abdominal aortic aneurysm: preliminary results from a randomized trial</TI>
<SO>Journal of Cardiopulmonary Rehabilitation and Prevention</SO>
<YR>2010</YR>
<VL>30</VL>
<NO>6</NO>
<PG>374-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nevitt-1989" MODIFIED="2015-01-14 09:05:35 +0000" MODIFIED_BY="[Empty name]" NAME="Nevitt 1989" TYPE="JOURNAL_ARTICLE">
<AU>Nevitt MP, Ballard DJ, Hallett JW Jr</AU>
<TI>Prognosis of abdominal aortic aneurysms. A population-based study</TI>
<SO>The New England Journal of Medicine</SO>
<YR>1989</YR>
<VL>321</VL>
<NO>15</NO>
<PG>1009-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Powell-2008" MODIFIED="2015-01-14 09:05:35 +0000" MODIFIED_BY="[Empty name]" NAME="Powell 2008" TYPE="JOURNAL_ARTICLE">
<AU>Powell JT, Brown LC, Greenhalgh RM, Thompson SG</AU>
<TI>The rupture rate of large abdominal aortic aneurysms: Is this modified by anatomical suitability for endovascular repair?</TI>
<SO>Annals of Surgery</SO>
<YR>2008</YR>
<VL>247</VL>
<NO>1</NO>
<PG>173-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Prinssen-2004" MODIFIED="2015-01-14 08:32:57 +0000" MODIFIED_BY="[Empty name]" NAME="Prinssen 2004" TYPE="JOURNAL_ARTICLE">
<AU>Prinssen M, Verhoeven EL, Buth J, Cuypers PW, van Sambeek MR, Balm R</AU>
<TI>A randomized trial comparing conventional and endovascular repair of abdominal aortic aneurysms</TI>
<SO>New England Journal of Medicine</SO>
<YR>2004</YR>
<VL>351</VL>
<NO>16</NO>
<PG>1607-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RESCAN-Collaborators-2013" MODIFIED="2015-01-14 09:05:35 +0000" MODIFIED_BY="[Empty name]" NAME="RESCAN Collaborators 2013" TYPE="JOURNAL_ARTICLE">
<AU>RESCAN Collaborators, Bown MJ, Sweeting MJ, Brown LC, Powell JT, Thompson SG</AU>
<TI>Surveillance intervals for small abdominal aortic aneurysms: a meta-analysis</TI>
<SO>JAMA</SO>
<YR>2013</YR>
<VL>309</VL>
<NO>8</NO>
<PG>806-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rudarakanchana-2013" MODIFIED="2014-04-30 21:31:34 +0100" MODIFIED_BY="[Empty name]" NAME="Rudarakanchana 2013" TYPE="JOURNAL_ARTICLE">
<AU>Rudarakanchana N, Powell JT</AU>
<TI>Advances in imaging and surveillance of AAA: when, how, how often?</TI>
<SO>Progress in Cardiovascular Diseases</SO>
<YR>2013</YR>
<VL>56</VL>
<NO>1</NO>
<PG>7-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shah-1997" MODIFIED="2015-01-14 09:05:35 +0000" MODIFIED_BY="[Empty name]" NAME="Shah 1997" TYPE="JOURNAL_ARTICLE">
<AU>Shah PK</AU>
<TI>Inflammation, metalloproteinases, and increased proteolysis: an emerging pathophysiological paradigm in aortic aneurysm</TI>
<SO>Circulation</SO>
<YR>1997</YR>
<VL>96</VL>
<NO>7</NO>
<PG>2115-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stonebridge-1996" MODIFIED="2012-01-31 12:32:59 +0000" MODIFIED_BY="[Empty name]" NAME="Stonebridge 1996" TYPE="BOOK_SECTION">
<AU>Stonebridge PA, Ruckley CV</AU>
<TI>Abdominal aortic aneurysms</TI>
<SO>A Textbook of Vascular Medicine</SO>
<YR>1996</YR>
<PG>176-90</PG>
<ED>Tooke JE, Lowe GDO</ED>
<PB>Arnold</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tew-2012" MODIFIED="2015-01-14 09:05:35 +0000" MODIFIED_BY="[Empty name]" NAME="Tew 2012" TYPE="JOURNAL_ARTICLE">
<AU>Tew GA, Moss J, Crank H, Mitchell PA, Nawaz S</AU>
<TI>Endurance exercise training in patients with small abdominal aortic aneurysm: a randomized controlled pilot study</TI>
<SO>Archives of Physical Medicine and Rehabilitation</SO>
<YR>2012</YR>
<VL>93</VL>
<NO>12</NO>
<PG>2148-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-U.S.-Preventive-Task-Force" MODIFIED="2015-01-14 09:05:35 +0000" MODIFIED_BY="[Empty name]" NAME="U.S. Preventive Task Force" TYPE="OTHER">
<AU>U.S. Preventive Services Task Force</AU>
<TI>Screening for abdominal aortic aneurysm</TI>
<SO>www.ahrq.gov/clinic/uspstf/uspsaneu.htm</SO>
<YR>(accessed 27 March 2008)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-UK-Screening" MODIFIED="2015-01-14 09:05:35 +0000" MODIFIED_BY="[Empty name]" NAME="UK Screening" TYPE="OTHER">
<TI>UK National Screening Committee statement on Prime Minister&#8217;s Health speech</TI>
<SO>www.nsc.nhs.uk/pdfs/NSC-pressrelease-080108.pdf</SO>
<YR>(accessed 30 March 2008)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-United-Kingdom-EVAR-Trial-Investigators-2010" MODIFIED="2015-01-14 08:33:11 +0000" MODIFIED_BY="[Empty name]" NAME="United Kingdom EVAR Trial Investigators 2010" TYPE="JOURNAL_ARTICLE">
<AU>United Kingdom EVAR Trial Investigators, Greenhalgh RM, Brown LC, Powell JT, Thompson SG, Epstein D</AU>
<TI>Endovascular repair of aortic aneurysm in patients physically ineligible for open repair</TI>
<SO>New England Journal of Medicine</SO>
<YR>2010</YR>
<VL>362</VL>
<NO>20</NO>
<PG>1872-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wilt-2006" MODIFIED="2008-07-05 06:27:59 +0100" MODIFIED_BY="[Empty name]" NAME="Wilt 2006" TYPE="OTHER">
<AU>Wilt TJ, Lederle FA, MacDonald R, Jonk YC, Rector TS, Kane RL</AU>
<TI>Comparison of endovascular and open surgical repairs for abdominal aortic aneurysm</TI>
<SO>Evidence Report/Technology Assessment</SO>
<YR>2006</YR>
<VL>144</VL>
<PG>1-113</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2014-04-04 08:23:59 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Ballard-1999" MODIFIED="2012-01-13 12:31:04 +0000" MODIFIED_BY="[Empty name]" NAME="Ballard 1999" TYPE="COCHRANE_REVIEW">
<AU>Ballard DJ, Filardo G, Fowkes FG, Powell JT</AU>
<TI>Surgery for small asymptomatic abdominal aortic aneurysms</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>1999</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2008-05-28 17:32:00 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-05-28 17:32:00 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001835"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ballard-2008" MODIFIED="2012-01-13 12:32:57 +0000" MODIFIED_BY="[Empty name]" NAME="Ballard 2008" TYPE="COCHRANE_REVIEW">
<AU>Ballard DJ, Filardo G, Fowkes G, Powell JT</AU>
<TI>Surgery for small asymptomatic abdominal aortic aneurysms</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2012-01-13 12:32:45 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-01-13 12:32:45 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001835.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Filardo-2011" MODIFIED="2014-04-04 08:23:57 +0100" MODIFIED_BY="[Empty name]" NAME="Filardo 2011" TYPE="COCHRANE_REVIEW">
<AU>Filardo G, Powell JT, Martinez MAM, Ballard DJ</AU>
<TI>Surgery for small asymptomatic abdominal aortic aneurysms</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2014-04-04 08:23:51 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-04-04 08:23:51 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001835.pub3"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2014-10-09 09:39:18 +0100" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2015-01-14 09:07:34 +0000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2015-01-14 09:07:34 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2015-01-14 09:06:58 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ADAM">
<CHAR_METHODS MODIFIED="2015-01-14 09:04:28 +0000" MODIFIED_BY="[Empty name]">
<P>Study design: intention to treat<BR/>Method of randomisation: equal probability of assignment to each of the two study groups using automated telephone/computer<BR/>Concealment of allocation: unblinded</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-14 09:06:58 +0000" MODIFIED_BY="[Empty name]">
<P>Country: United States<BR/>Number: 1136<BR/>Age: 50 to 79 years<BR/>Sex: men (n = 1126) and women (n = 10)<BR/>Inclusion criteria: small (4.0 cm to 5.5 cm) non-tender asymptomatic AAAs considered fit for immediate surgery. Patients who were considered unfit for immediate surgery, had symptoms associated the aneurysm, were unable to attend the follow-up visit, or were unable to give informed consent were excluded. Patients who received a revascularization procedure within 3 months of enrolment, who had a myocardial infarction within 6 months of enrolment, or who were expected to survive less than 5 years because of invasive cancer or other life-threatening disease were also excluded.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-14 09:04:36 +0000" MODIFIED_BY="[Empty name]">
<P>Treatment: surgery, n = 569 of whom 527 had immediate aneurysm repair; 42 had no elective operation due to death, refusal, etc.<BR/>Surveillance, n = 567 of whom 349 had aneurysm repair when they met the criteria listed below (in 9%, the procedures were performed despite an AAA that did not meet the repair criteria listed below).<BR/>Participants assigned to the immediate-surgery group received standard open repair within 6 weeks after randomisation, while participants assigned to selective surveillance were followed without repair at similar regular intervals (at minimum once every 6 months), and surgery was performed within 6 weeks if: a) the aneurysm reached 5.5 cm; or b) the aneurysm enlarged by a minimum of 0.7 cm in 6 months or 1.0 cm in 1 year; or c) the aneurysm became symptomatic.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-14 09:04:36 +0000" MODIFIED_BY="[Empty name]">
<P>Primary: survival during mean follow-up (range 3.5 to 8.0 years, mean 4.9 years)<BR/>(30-day surgical mortality)<BR/>Secondary: healthcare costs</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-10-23 12:39:01 +0100" MODIFIED_BY="[Empty name]">
<P>Supported by the Cooperative Studies Program of the Department of Veterans Affairs Office of Research and Development, Washington, DC, USA</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-14 09:04:47 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-CAESAR">
<CHAR_METHODS MODIFIED="2015-01-14 09:04:42 +0000" MODIFIED_BY="[Empty name]">
<P>Study design: intention to treat</P>
<P>Method of randomisation: Randomisation was designed with equal probability (1:1 ratio) of assignment to either immediate endovascular repair or surveillance by means of a computed-generated random number list, stratified by centre using a permuted block design and carried out online through the Internet.        </P>
<P>Concealment of allocation: unblinded</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-14 09:04:44 +0000" MODIFIED_BY="[Empty name]">
<P>Country: Italy</P>
<P>Number: 360</P>
<P>Sex: men (n = 345) and women (n = 15)</P>
<P>Age: 50 to 79 years</P>
<P>Inclusion criteria: people with small (4.1 cm to 5.4 cm) asymptomatic AAAs, without high surgical risk, and who would have benefited from immediate repair. Patients were excluded if they had severe co-morbidities or a suprarenal/thoracic aorta &#8805; 4.0 cm, needed urgent repair, or were unable or unwilling to give informed consent or follow the protocol.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-14 09:04:46 +0000" MODIFIED_BY="[Empty name]">
<P>Treatment: surgery, n = 182 of whom 175 had immediate endovascular surgery; 6 declined treatment and 1 underwent open repair according to person's choice.</P>
<P>Surveillance, n = 178 of whom 172 had aneurysm repair when they met the criteria below (6 patients had endovascular repair against protocol: 5 per patient choice and 1 with a surgeon not participating in the study).</P>
<P>Participants assigned to immediate endovascular repair underwent aneurysm repair a median of 22 days after randomisation, while participants assigned to surveillance were seen every 6 months and repair allowed if the aneurysm grew to 5.5 cm diameter in size, rapidly increased in diameter (&gt; 1 cm/year), or became symptomatic.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-14 09:04:47 +0000" MODIFIED_BY="[Empty name]">
<P>Primary: mortality from any cause</P>
<P>Secondary: 1) aneurysm-related deaths (defined as death caused directly or indirectly by aneurysm rupture or aneurysm repair), 2) aneurysm rupture, 3) perioperative (30 days or inpatient) or late adverse events (defined according to SVS/AAVS reporting standards), 4) conversion to open repair, 5) loss of treatment options (anatomical suitability for endovascular repair), and 6) aneurysm growth rate</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-14 09:05:00 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-PIVOTAL">
<CHAR_METHODS MODIFIED="2015-01-14 09:04:54 +0000" MODIFIED_BY="[Empty name]">
<P>Study design: intention to treat</P>
<P>Method of randomisation: The randomisation procedure was created with equal probability of assignment to each of the treatment groups by means of a computer-generated random-number code.</P>
<P>Concealment of allocation: unblinded</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-14 09:04:56 +0000" MODIFIED_BY="[Empty name]">
<P>Country: United States</P>
<P>Number: 728</P>
<P>Sex: men (n = 631) and women (n = 97)</P>
<P>Age: 40 to 90 years</P>
<P>Inclusion criteria: people with small (4.0 cm to 5.0 cm) AAAs. Patients were excluded from the study if they had evidence of symptoms referable to the aneurysm, an abdominal or thoracic repair, an aneurysm originating &#8804; 1.0 cm from the most distal main renal artery, life expectancy of &lt; 3 years, inability to provide informed consent, predicted noncompliance with the protocol, SVS score &gt; 2 with the exception of age and controlled hypertension, baseline serum creatinine level &gt; 2.5 mg/dL, or when the patient did not meet the indications for use of the endograft device.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-14 09:04:59 +0000" MODIFIED_BY="[Empty name]">
<P>Treatment: surgery, n = 366 of whom 322 had immediate endovascular surgery; 4 underwent open surgery, 6 underwent repair outside of the 30-day window of randomisation, 9 were withdrawn per patient request, 10 were withdrawn per physician request for deteriorating health status between randomisation and scheduled repair, 2 were treated with an endograft device that was not in the protocol, and 13 received no repair for reasons not specified.</P>
<P>Surveillance, n = 362 of whom 100 had aneurysm repair when they met the criteria listed below.</P>
<P>Participants assigned to immediate endovascular repair underwent aneurysm repair &#8804; 30 days of randomisation, while participants assigned to surveillance were seen at 1 month, 6 months, and every 6 months thereafter for a minimum of 36 months and a maximum of 60 months after operation. Participants were offered aneurysm repair when symptoms thought referable to the aneurysm developed, when the diameter of the aneurysm reached 5.5 cm, or when the aneurysm enlarged &#8805; 0.5 cm between any 2 6-month assessments.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-14 09:05:00 +0000" MODIFIED_BY="[Empty name]">
<P>Primary: to determine whether immediate endovascular repair of aneurysms 4.0 cm to 5.0 cm in diameter is superior to surveillance with respect to the frequency of rupture or aneurysm-related death.</P>
<P>Secondary: N/A</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-08-28 18:40:38 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-14 09:07:27 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-UKSAT">
<CHAR_METHODS MODIFIED="2015-01-14 09:05:05 +0000" MODIFIED_BY="[Empty name]">
<P>Study design: intention to treat<BR/>Method of randomisation: concealed randomisation using automated telephone/computer<BR/>Concealment of allocation: unblinded</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-14 09:07:27 +0000" MODIFIED_BY="[Empty name]">
<P>Country: United Kingdom<BR/>Number: 1090<BR/>Sex: men (n = 902) and women (n = 188)<BR/>Age: 60 to 76 years<BR/>Inclusion criteria: asymptomatic (non-tender) infrarenal aneurysm. Maximum anteroposterior diameter 4.0 cm to 5.5 cm. Fit for elective surgery.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-14 09:05:11 +0000" MODIFIED_BY="[Empty name]">
<P>Treatment: surgery, n = 563 of whom 528 had immediate aneurysm repair; 35 had no elective operation due to death, refusal, etc.<BR/>Control: surveillance, n = 527 of whom 401 had aneurysm repair when they met the criteria listed below.<BR/>Participants assigned to the immediate-surgery group received standard open repair within 6 weeks after randomisation, while participants assigned to selective surveillance were followed without repair at similar regular intervals (at minimum once every 6 months), and surgery was performed within 6 weeks if: a) the aneurysm reached 5.5 cm; or b) the aneurysm enlarged by a minimum 1.0 cm in 1 year; or c) the aneurysm became tender or symptomatic.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-14 09:05:11 +0000" MODIFIED_BY="[Empty name]">
<P>Primary: survival during mean follow-up (range 8 to 12 years, mean 10 years)<BR/>(30-day surgical mortality)<BR/>Secondary: healthcare costs</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-01-14 09:05:11 +0000" MODIFIED_BY="[Empty name]">
<P>The Medical Research Council and the British Heart Foundation supported this trial.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>AAVS: American Association for Vascular Surgery<BR/>SVS: The Society for Vascular Surgery</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2015-01-14 09:05:17 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2015-01-14 09:05:17 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Canadian-Trial">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-14 09:05:17 +0000" MODIFIED_BY="[Empty name]">
<P>This trial was begun but stopped because of an inadequate rate of recruitment after n = 104 had been enrolled (Cole CW, personal communication, 1998).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2011-10-07 21:46:43 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2011-10-11 17:59:56 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2015-01-14 09:07:34 +0000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2015-01-14 09:05:00 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-14 09:04:36 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-ADAM">
<DESCRIPTION>
<P>The method of randomisation was of equal probability of assignment to each of the two study groups using automated telephone/computer.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-14 08:55:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-CAESAR">
<DESCRIPTION>
<P>Randomisation was designed with equal probability (1:1 ratio) of assignment to either immediate endovascular repair or surveillance by means of a computed-generated random number list, stratified by centre using a permuted block design and carried out online through the Internet.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-14 09:05:00 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-PIVOTAL">
<DESCRIPTION>
<P>The randomisation procedure was designed to provide equal probability of assignment to each of the treatment groups by means of a computer-generated random-number code.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-28 18:43:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-UKSAT">
<DESCRIPTION>
<P>Concealed randomisation using automated telephone/computer</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2014-09-29 22:36:10 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-28 18:39:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-ADAM">
<DESCRIPTION>
<P>Concealment of allocation: unblinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-28 18:40:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-CAESAR">
<DESCRIPTION>
<P>Concealment of allocation: unblinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-28 18:40:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-PIVOTAL">
<DESCRIPTION>
<P>Concealment of allocation: unblinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-28 18:43:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-UKSAT">
<DESCRIPTION>
<P>Concealment of allocation: unblinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2014-09-29 22:36:10 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-17 15:14:02 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-ADAM">
<DESCRIPTION>
<P>Cannot blind participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-07 22:36:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-CAESAR">
<DESCRIPTION>
<P>Cannot blind participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-07 22:36:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-PIVOTAL">
<DESCRIPTION>
<P>Cannot blind participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-08-28 18:43:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-UKSAT">
<DESCRIPTION>
<P>Cannot blind participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2015-01-14 09:07:34 +0000" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-01-14 09:07:05 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-ADAM">
<DESCRIPTION>
<P>Unlikely given the study outcome (mortality) and low lost-to-follow-up rate. Vital status was assessed using the same methodology for both participants in the immediate-repair group and participants in the routine ultrasound surveillance group--in case misclassification occurred this would have been non-differential and its impact on the study results would be limited.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-01-14 09:07:12 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-CAESAR">
<DESCRIPTION>
<P>Unlikely given the study outcome (mortality) and low lost-to-follow-up rate. Vital status was assessed using the same methodology for both participants in the immediate-repair group and participants in the routine ultrasound surveillance group-&#8211;in case misclassification occurred this would have been non-differential and its impact on the study results would be limited.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-01-14 09:07:21 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-PIVOTAL">
<DESCRIPTION>
<P>Unlikely given the study outcome (mortality) and low lost-to-follow-up rate. Vital status was assessed using the same methodology for both participants in the immediate-repair group and participants in the routine ultrasound surveillance group--in case misclassification occurred, this would have been non-differential and its impact on the study results would be limited.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-01-14 09:07:34 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-UKSAT">
<DESCRIPTION>
<P>Unlikely given the study outcome (mortality) and low lost-to-follow-up rate. Vital status was assessed using the same methodology for both participants in the immediate-repair group and participants in the routine ultrasound surveillance group--in case misclassification occurred, this would have been non-differential and its impact on the study results would be limited.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2015-01-14 09:05:16 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-14 09:04:40 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-ADAM">
<DESCRIPTION>
<P>Unlikely given the study outcome (mortality) and low lost-to-follow-up rate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-14 09:04:52 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-CAESAR">
<DESCRIPTION>
<P>Unlikely given the study outcome (mortality) and low lost-to-follow-up rate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-14 09:05:04 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-PIVOTAL">
<DESCRIPTION>
<P>Unlikely given the study outcome (mortality) and low lost-to-follow-up rate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-14 09:05:16 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-UKSAT">
<DESCRIPTION>
<P>Unlikely given the study outcome (mortality) and low lost-to-follow-up rate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2015-01-14 09:05:16 +0000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-14 09:04:40 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-ADAM">
<DESCRIPTION>
<P>Authors published findings on all the study outcomes including the study outcome of this review.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-14 09:04:52 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-CAESAR">
<DESCRIPTION>
<P>Authors published findings on the main study outcome of this review.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-14 09:05:04 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-PIVOTAL">
<DESCRIPTION>
<P>Authors published findings on the main study outcome of this review.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-14 09:05:16 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-UKSAT">
<DESCRIPTION>
<P>Authors published findings on all the study outcomes including the study outcome of this review.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2015-01-14 09:05:16 +0000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-14 09:04:41 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-ADAM">
<DESCRIPTION>
<P>We did not identify other possible risk of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-14 09:04:53 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-CAESAR">
<DESCRIPTION>
<P>Conflicts of interest: The sponsor of the study, Cook Medical, withdrew.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-14 09:05:04 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-PIVOTAL">
<DESCRIPTION>
<P>Conflicts of interest: The study was funded by Medtronic Vascular, which now holds the trial database. The funding source was not specified in the report of trial results, but was specified in the 2009 paper describing the rationale and protocol for the study (<LINK REF="STD-PIVOTAL" TYPE="STUDY">PIVOTAL</LINK>). In addition, two members of the research team were acknowledged as paid consultants of Medtronic.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-14 09:05:16 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-UKSAT">
<DESCRIPTION>
<P>We did not identify other possible risk of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2014-10-11 02:10:33 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2014-10-09 09:29:35 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Immediate EVAR repair versus ultrasound surveillance at one year</NAME>
<DICH_OUTCOME CHI2="0.11053130408231225" CI_END="2.1723378562782893" CI_START="0.6038048776647775" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1452808361081912" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.33692737050548655" LOG_CI_START="-0.21910338297515822" LOG_EFFECT_SIZE="0.05891199376516417" METHOD="MH" MODIFIED="2014-10-09 09:29:35 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7395401026756793" P_Q="1.0" P_Z="0.6779075584506569" Q="0.0" RANDOM="NO" SCALE="47.98525381885596" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="410" TOTAL_2="421" WEIGHT="100.0" Z="0.41532014304740905">
<NAME>Mortality</NAME>
<GROUP_LABEL_1>Immediate Repair</GROUP_LABEL_1>
<GROUP_LABEL_2>Surveillance</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours immediate repair</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours surveillance</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.11053130408231225" CI_END="2.1723378562782893" CI_START="0.6038048776647775" DF="1" EFFECT_SIZE="1.1452808361081912" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="17" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="0.33692737050548655" LOG_CI_START="-0.21910338297515822" LOG_EFFECT_SIZE="0.05891199376516417" MODIFIED="2014-10-09 09:29:35 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7395401026756793" P_Z="0.6779075584506569" STUDIES="2" TAU2="0.0" TOTAL_1="410" TOTAL_2="421" WEIGHT="100.0" Z="0.41532014304740905">
<NAME>EVAR repair</NAME>
<DICH_DATA CI_END="3.3884837490278636" CI_START="0.49408128156689923" EFFECT_SIZE="1.2939035486806187" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" LOG_CI_END="0.5300054071298148" LOG_CI_START="-0.30620159918930095" LOG_EFFECT_SIZE="0.11190190397025693" MODIFIED="2014-04-09 00:58:42 +0100" MODIFIED_BY="[Empty name]" ORDER="191" O_E="0.0" SE="0.4911921348032875" STUDY_ID="STD-CAESAR" TOTAL_1="157" TOTAL_2="158" VAR="0.24126971329261096" WEIGHT="41.57403701080765"/>
<DICH_DATA CI_END="2.4549977199515802" CI_START="0.4401689072545675" EFFECT_SIZE="1.0395256916996047" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" LOG_CI_END="0.39005109311360764" LOG_CI_START="-0.3563806384857277" LOG_EFFECT_SIZE="0.016835227313939948" MODIFIED="2014-04-09 00:58:58 +0100" MODIFIED_BY="[Empty name]" ORDER="192" O_E="0.0" SE="0.4384576940381115" STUDY_ID="STD-PIVOTAL" TOTAL_1="253" TOTAL_2="263" VAR="0.19224514946121823" WEIGHT="58.42596298919236"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2014-10-11 02:10:33 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Costs of immediate repair versus ultrasound surveillance</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.01" MODIFIED="2014-10-09 10:12:17 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="929" TOTAL_2="889" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Health service costs</NAME>
<GROUP_LABEL_1>Immediate repair</GROUP_LABEL_1>
<GROUP_LABEL_2>Surveillance</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours immediate repair</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours surveillance</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.01.01" MODIFIED="2014-10-09 10:12:12 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="563" TOTAL_2="527" WEIGHT="0.0" Z="0.0">
<NAME>Open repair (GBP)</NAME>
<CONT_DATA CI_END="1331.6810362891695" CI_START="796.3189637108305" EFFECT_SIZE="1064.0" ESTIMABLE="YES" MEAN_1="4978.0" MEAN_2="3914.0" ORDER="1325" SD_1="1865.0" SD_2="2564.0" SE="136.5744668782709" STUDY_ID="STD-UKSAT" TOTAL_1="563" TOTAL_2="527" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.01.02" MODIFIED="2014-10-09 10:12:17 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="366" TOTAL_2="362" WEIGHT="0.0" Z="0.0">
<NAME>Endovascular repair (USD)</NAME>
<CONT_DATA CI_END="13156.949056223093" CI_START="-8042.949056223093" EFFECT_SIZE="2557.0" ESTIMABLE="YES" MEAN_1="48669.0" MEAN_2="46112.0" MODIFIED="2014-04-26 00:52:35 +0100" MODIFIED_BY="[Empty name]" ORDER="19" SD_1="72960.0" SD_2="72960.0" SE="5408.236651200807" STUDY_ID="STD-PIVOTAL" TOTAL_1="366" TOTAL_2="362" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2015-01-14 09:07:35 +0000" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2015-01-14 09:05:35 +0000" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAoIAAAM5CAYAAACTilAXAAB3OklEQVR42uydAURf3///f8xMZmYk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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2015-01-14 09:07:35 +0000" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl4AAAEACAMAAABVk4iuAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2015-01-14 09:07:35 +0000" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAARsAAAHNCAIAAAChKEhEAAAS70lEQVR42u3dv45cxRLH8ZWQrgg2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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2015-01-14 09:07:35 +0000" MODIFIED_BY="[Empty name]" NO="4" REF_ID="CMP-001.01" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;SHOW_ROB_TABLE:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: Immediate repair (either EVAR or open surgery) versus ultrasound surveillance at one year, outcome: 1.1 Mortality.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA1wAAADwCAMAAAAjDZX+AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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=
</FILE>
</FIGURE>
<FIGURE FILENAME="UKSAT ADAM pooled patient-level plot revised.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2014-12-05 09:18:32 +0000" MODIFIED_BY="[Empty name]" NO="5" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Forest plot of comparison: Immediate repair (open surgery) versus ultrasound surveillance at six years.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA+EAAACQCAIAAADoTf1IAAAjsUlEQVR42u2drXLkPBaGw5cPXx7W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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2014-02-13 15:11:54 +0000" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2014-02-13 15:11:54 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2011-06-21 12:22:41 +0100" MODIFIED_BY="Karen Welch">CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-02-13 15:11:54 +0000" MODIFIED_BY="[Empty name]">
<TABLE COLS="3" ROWS="28">
<TR>
<TD>
<P>#1</P>
</TD>
<TD>
<P>MeSH descriptor: [Endovascular Procedures] explode all trees</P>
</TD>
<TD ALIGN="RIGHT">
<P>6017</P>
</TD>
</TR>
<TR>
<TD>
<P>#2</P>
</TD>
<TD>
<P>MeSH descriptor: [Stents] explode all trees</P>
</TD>
<TD ALIGN="RIGHT">
<P>3314</P>
</TD>
</TR>
<TR>
<TD>
<P>#3</P>
</TD>
<TD>
<P>MeSH descriptor: [Vascular Surgical Procedures] this term only</P>
</TD>
<TD ALIGN="RIGHT">
<P>652</P>
</TD>
</TR>
<TR>
<TD>
<P>#4</P>
</TD>
<TD>
<P>MeSH descriptor: [Blood Vessel Prosthesis] explode all trees</P>
</TD>
<TD ALIGN="RIGHT">
<P>452</P>
</TD>
</TR>
<TR>
<TD>
<P>#5</P>
</TD>
<TD>
<P>MeSH descriptor: [Blood Vessel Prosthesis Implantation] this term only</P>
</TD>
<TD ALIGN="RIGHT">
<P>508</P>
</TD>
</TR>
<TR>
<TD>
<P>#6</P>
</TD>
<TD>
<P>endovasc*:ti,ab,kw</P>
</TD>
<TD ALIGN="RIGHT">
<P>941</P>
</TD>
</TR>
<TR>
<TD>
<P>#7</P>
</TD>
<TD>
<P>endostent*:ti,ab,kw</P>
</TD>
<TD ALIGN="RIGHT">
<P>1</P>
</TD>
</TR>
<TR>
<TD>
<P>#8</P>
</TD>
<TD>
<P>(stent* or graft* or endograft*):ti,ab,kw</P>
</TD>
<TD ALIGN="RIGHT">
<P>18089</P>
</TD>
</TR>
<TR>
<TD>
<P>#9</P>
</TD>
<TD>
<P>(surger* or surgic* or repair):ti,ab,kw</P>
</TD>
<TD ALIGN="RIGHT">
<P>88118</P>
</TD>
</TR>
<TR>
<TD>
<P>#10</P>
</TD>
<TD>
<P>(EVAR):ti,ab,kw</P>
</TD>
<TD ALIGN="RIGHT">
<P>74</P>
</TD>
</TR>
<TR>
<TD>
<P>#11</P>
</TD>
<TD>
<P>RAAA:ti,ab,kw</P>
</TD>
<TD ALIGN="RIGHT">
<P>5</P>
</TD>
</TR>
<TR>
<TD>
<P>#12</P>
</TD>
<TD>
<P>(EVRAR):ti,ab,kw</P>
</TD>
<TD ALIGN="RIGHT">
<P>1</P>
</TD>
</TR>
<TR>
<TD>
<P>#13</P>
</TD>
<TD>
<P>endoprosthe*:ti,ab,kw</P>
</TD>
<TD ALIGN="RIGHT">
<P>203</P>
</TD>
</TR>
<TR>
<TD>
<P>#14</P>
</TD>
<TD>
<P>Palmaz:ti,ab,kw</P>
</TD>
<TD ALIGN="RIGHT">
<P>91</P>
</TD>
</TR>
<TR>
<TD>
<P>#15</P>
</TD>
<TD>
<P>Zenith or Dynalink or Hemobahn or Luminex* or Memotherm or Wallstent:ti,ab,kw</P>
</TD>
<TD ALIGN="RIGHT">
<P>128</P>
</TD>
</TR>
<TR>
<TD>
<P>#16</P>
</TD>
<TD>
<P>Viabahn or Nitinol or Hemobahn or Intracoil or Tantalum:ti,ab,kw</P>
</TD>
<TD ALIGN="RIGHT">
<P>155</P>
</TD>
</TR>
<TR>
<TD>
<P>#17</P>
</TD>
<TD>
<P>MeSH descriptor: [Ultrasonography, Doppler] explode all trees</P>
</TD>
<TD ALIGN="RIGHT">
<P>2391</P>
</TD>
</TR>
<TR>
<TD>
<P>#18</P>
</TD>
<TD>
<P>MeSH descriptor: [Ultrasonography] this term only</P>
</TD>
<TD ALIGN="RIGHT">
<P>816</P>
</TD>
</TR>
<TR>
<TD>
<P>#19</P>
</TD>
<TD>
<P>MeSH descriptor: [Tomography] explode all trees</P>
</TD>
<TD ALIGN="RIGHT">
<P>10690</P>
</TD>
</TR>
<TR>
<TD>
<P>#20</P>
</TD>
<TD>
<P>screen* or ultrasound or scan* or surveillance</P>
</TD>
<TD ALIGN="RIGHT">
<P>61201</P>
</TD>
</TR>
<TR>
<TD>
<P>#21</P>
</TD>
<TD>
<P>#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20</P>
</TD>
<TD ALIGN="RIGHT">
<P>162640</P>
</TD>
</TR>
<TR>
<TD>
<P>#22</P>
</TD>
<TD>
<P>MeSH descriptor: [Aortic Aneurysm] explode all trees</P>
</TD>
<TD ALIGN="RIGHT">
<P>767</P>
</TD>
</TR>
<TR>
<TD>
<P>#23</P>
</TD>
<TD>
<P>aneurysm* near/4 (abdom* or thoracoabdom* or thoraco-abdom* or aort*)</P>
</TD>
<TD ALIGN="RIGHT">
<P>1154</P>
</TD>
</TR>
<TR>
<TD>
<P>#24</P>
</TD>
<TD>
<P>(aort* near/3 (ballon* or dilat* or bulg*))</P>
</TD>
<TD ALIGN="RIGHT">
<P>69</P>
</TD>
</TR>
<TR>
<TD>
<P>#25</P>
</TD>
<TD>
<P>AAA</P>
</TD>
<TD ALIGN="RIGHT">
<P>453</P>
</TD>
</TR>
<TR>
<TD>
<P>#26</P>
</TD>
<TD>
<P>MeSH descriptor: [Aorta, Abdominal] explode all trees and with qualifier(s): [Surgery - SU]</P>
</TD>
<TD ALIGN="RIGHT">
<P>179</P>
</TD>
</TR>
<TR>
<TD>
<P>#27</P>
</TD>
<TD>
<P>#22 or #23 or #24 or #25 or #26</P>
</TD>
<TD ALIGN="RIGHT">
<P>1458</P>
</TD>
</TR>
<TR>
<TD>
<P>#28</P>
</TD>
<TD>
<P>#21 and #27 in Trials</P>
</TD>
<TD ALIGN="RIGHT">
<P>836</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;4 studies were included in the quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="237">
<FLOWCHARTBOX TEXT="&lt;p&gt;4 studies included in qualitative analysis&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;4 studies included in previous version of review&lt;/p&gt;"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;3 full-text records assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;784 records screened by TSC&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;784 records after duplicates removed&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;836 records identified from CENTRAL&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;1 record identified from Specialised Register&lt;/p&gt;&lt;p&gt;2 records identified by review authors&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;781 records deemed not relevant or new for this update&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;0 additional studies excluded&lt;/p&gt;&lt;p&gt;1 additional record to a previously included study&lt;/p&gt;&lt;p&gt;2 records added to additional publications&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>